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A B S T R A C T
Background
People with severe mental illness are twice as likely to develop type 2 diabetes as those without severe mental illness. Treatment
guidelines for type 2 diabetes recommend that structured education should be integrated into routine care and should be offered to all.
However, for people with severe mental illness, physical health may be a low priority, and motivation to change may be limited. These
additional challenges mean that the findings reported in previous systematic reviews of diabetes self management interventions may
not be generalised to those with severe mental illness, and that tailored approaches to effective diabetes education may be required for
this population.
Objectives
To assess the effects of diabetes self management interventions specifically tailored for people with type 2 diabetes and severe mental
illness.
Search methods
We searched the Cochrane Library, MEDLINE, EMBASE, PsycINFO, the Cumulative Index to Nursing and Allied Health Literature
(CINAHL), the International Clinical Trials Registry Platform (ICTRP) Search Portal, ClinicalTrials.gov and grey literature. The date
of the last search of all databases was 07 March 2016.
Selection criteria
Randomised controlled trials of diabetes self management interventions for people with type 2 diabetes and severe mental illness.
Data collection and analysis
Two review authors independently screened abstracts and full-text articles, extracted data and conducted the risk of bias assessment. We
used a taxonomy of behaviour change techniques and the framework for behaviour change theory to describe the theoretical basis of
the interventions and active ingredients. We used the GRADE method (Grades of Recommendation, Assessment, Development and
Evaluation Working Group) to assess trials for overall quality of evidence.
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Main results
We included one randomised controlled trial involving 64 participants with schizophrenia or schizoaffective disorder. The average age
of participants was 54 years; participants had been living with type 2 diabetes for on average nine years, and with their psychiatric
diagnosis since theywere on average 28 years of age. Investigators evaluated the 24-weekDiabetes Awareness and Rehabilitation Training
(DART) programme in comparison with usual care plus information (UCI). Follow-up after trial completion was six months. Risk of
bias was mostly unclear but was high for selective reporting. Trial authors did not report on diabetes-related complications, all-cause
mortality, adverse events, health-related quality of life nor socioeconomic effects. Twelve months of data on self care behaviours as
measured by total energy expenditure showed a mean of 2148 kcal for DART and 1496 kcal for UCI (52 participants; very low-quality
evidence), indicating no substantial improvement. The intervention did not have a substantial effect on glycosylated haemoglobin
A1c (HbA1c) at 6 or 12 months of follow-up (12-month HbA1c data 7.9% for DART vs 6.9% for UCI; 52 participants; very low-
quality evidence). Researchers noted small improvements in body mass index immediately after the intervention was provided and
at six months, along with improved weight post intervention. Diabetes knowledge and self efficacy improved immediately following
receipt of the intervention, and knowledge also at six months. The intervention did not improve blood pressure.
Authors’ conclusions
Evidence is insufficient to show whether type 2 diabetes self management interventions for people with severe mental illness are effective
in improving outcomes. Researchers must conduct additional trials to establish efficacy, and to identify the active ingredients in these
interventions and the people most likely to benefit from them.
P L A I N L A N G U A G E S U M M A R Y
Self management interventions for type 2 diabetes in adults with severe mental illness
Review question
What are the effects of diabetes self management interventions specifically tailored for adults with type 2 diabetes and severe mental
illness?
Background
Diabetes is one of the most common long-term conditions, affecting around 415 million people worldwide. People with severe mental
illness are twice as likely to develop diabetes as those without mental health problems because of many factors, including antipsychotic
medication side effects and inadequate ’lifestyle’ such as poor diet and low levels of physical activity. Once diagnosed, type 2 diabetes is
managed through a combination of medication and behavioural changes. When diabetes is poorly managed, people can develop severe
and life-threatening complications. Healthcare providers have developed patient education programmes to help people to self manage
their diabetes, and to reduce the likelihood of these complications. Although many programmes for type 2 diabetes have been found
to be effective, little is known about programmes that have been specifically tailored to meet the needs of people with severe mental
illness.
Study characteristics
We identified one study, which recruited 64 adults with type 2 diabetes and schizophrenia or schizoaffective disorder. Researchers
compared usual care plus information leaflets with a 24-week education programme delivered once a week for 90 minutes (Diabetes
Awareness and Rehabilitation Training). This programme provided basic diabetes education and information about nutrition and
exercise. The average age of participants was 54 years; participants had been living with type 2 diabetes for on average nine years and
with their psychiatric diagnosis since they were on average 28 years old. People in the included study were monitored for six months
after the programme ended.
This evidence is up to date as of 07 March 2016.
Key results
In summary, few studies have evaluated the effects of diabetes self management programmes for adults with severe mental illness.
Study authors of the single included study did not report diabetes-related complications, all-cause mortality, adverse events, health-
related quality of life nor socioeconomic effects. They described small improvements in body mass index and body weight, as well as
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in diabetes knowledge and self efficacy. Current evidence is insufficient to show that these types of programmes can help people with
type 2 diabetes and severe mental illness to better manage their diabetes and its consequences.
Quality of the evidence
We rated the overall quality of the evidence as very low, mainly because of the small numbers of included studies and participants, and
because reported study results showed inconsistency.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Self management interventions for type 2 diabetes in adult people with severe mental illness
Population: adults with type 2 diabetes and severe mental illness
Setting: community
Intervention: diabetes self management
Comparison: usual care + information
Outcomes Usual care + informa-
tion
Diabetes self manage-
ment
Relative effect
(95% CI)
Number of participants
(trials)
Quality of the evidence
(GRADE)
Comments
Diabetes- related com-
plications
See comment See comment See comment See comment See comment Not reported
All- cause mortality See comment See comment See comment See comment See comment Not reported
Adverse events See comment See comment See comment See comment See comment Not reported
Health- related quality
of life
See comment See comment See comment See comment See comment Not reported
Self care behaviours:
physical activity
(measured by total en-
ergy expenditure in
kcal)
Follow-up: 6 months (6
months af ter the end of
the intervent ion)
Mean energy expendi-
ture was 2148 kcal
Mean energy expen-
diture was 652 kcal
higher
- 52 (1) ⊕©©©
Very lowa
Trial authors stated
that this dif f erence re-
f lected no improvement
HbA1c [%]
Follow-up: 6 months (6
months af ter the end of
the intervent ion)
Mean HbA1c was 7.9% Mean HbA1c was 1%
lower
- 52 (1) ⊕©©©
Very lowa
Trial authors stated
that this dif f erence re-
f lected no improvement
Socioeconomic effects See comment See comment See comment See comment See comment Not reported
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CI: conf idence interval; HbA1c: glycosylated haemoglobin A1c; kcal: kilocalories
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our conf idence in the est imate of ef fect
M oderate quality: Further research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate
Low quality: Further research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate
Very low quality: We are very uncertain about the est imate
aDowngraded by three levels because of select ive report ing bias, indirectness and imprecision
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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B A C K G R O U N D
Description of the condition
Diabetes is a common and serious global health problem, currently
affecting an estimated 9% of adults - 415 million people world-
wide - and taking up 12% of international health expenditures
(International Diabetes Federation 2015). In high-income coun-
tries, approximately 87% to 91% of all people with diabetes are es-
timated to have type 2 diabetes (International Diabetes Federation
2015). The condition typically develops in adulthood, usually in
people over the age of 40 years, but younger onset is becoming
more common.Diabetes is characterised by poorly regulated blood
glucose levels, which may arise from defects in insulin secretion
(insulin deficiency), in its action (insulin resistance) or both. The
aim of treatment is to manage blood glucose levels to alleviate
short-term symptoms while preventing or delaying the develop-
ment of long-term complications. Individuals can initially control
elevated glucose in the blood, known as hyperglycaemia, through
lifestyle management, such as changes to diet and exercise, but
given the progressive nature of type 2 diabetes, it is likely that most
individuals will ultimately require pharmacological intervention
as well. This may initially consist of oral hypoglycaemic drugs and,
if the disease remains uncontrolled, insulin therapy.
The primary symptoms of type 2 diabetes are increased thirst and
urination; however, not all individuals will experience these symp-
toms. Therefore, many people remain undiagnosed for a sustained
period of time. Undetected hyperglycaemia can have implications
for the outcome of diabetes, including greater risk of macrovas-
cular and microvascular complications. Microvascular complica-
tions that primarily affect people with type 2 diabetes involve the
eyes, kidneys and nervous system, and include coronary heart dis-
ease and major stroke (The Emerging Risk Factors Collaboration
2010).
The prevalence of type 2 diabetes is increasing rapidly worldwide
and is predicted to more than double in the years between 2000
and 2030 (Wild 2004). Although no single causal factor has been
attributed to development of the condition, increasing urbanisa-
tion and ageing populations are strongly linked to global changes
in the incidence and prevalence of diabetes. One important risk
factor is a diagnosis of severe mental illness such as schizophrenia,
bipolar disorder or other psychoses, with research suggesting an
almost two-fold increase in the risk of diabetes among people with
severe mental illness (Osborn 2008). This increased risk has been
linked to a combination of factors including patient behaviour,
in particular physical inactivity and poor diet (De Hert 2011)
and higher rates of smoking (Lawrence 2009). Alongside lifestyle
and behavioural factors, medications commonly prescribed for se-
vere mental illness are strongly associated with development of
metabolic abnormalities and weight gain, which significantly in-
crease the risk of type 2 diabetes (De Hert 2011).
The World Health Organization (WHO) recognises mental dis-
order as an important contributing factor to the global burden of
non-communicable diseases, such as diabetes, and emphasises that
equitable access to effective programmes and healthcare interven-
tions is needed (WHO 2013a). As such, the WHO Comprehen-
siveMental Health Action Plan for 2013 to 2020 states that devel-
oping good-quality mental health services requires the use of evi-
dence-based protocols and practices. This plan suggests that health
workers must not limit interventions to those that improvemental
health but must also attend to the physical health needs of people
with a mental disorder (WHO 2013b). In the United Kingdom,
the Schizophrenia Commission (The Schizophrenia Commission
2012) and the Royal College of Psychiatrists (Royal College of
Psychiatrists 2009) recognise that the poorer physical health of
people with severe mental illness must be urgently addressed, and
they include amongst their advice the need for tailored health pro-
motion programmes that can help people to manage better their
physical health, including chronic illnesses.
Given the importance of lifestyle changes in the management of
type 2 diabetes, it is essential that people possess the skills needed
to manage their condition. Patient education and self manage-
ment are an integral part of diabetes care. People with type 2
diabetes have the right to receive education about their condi-
tion and treatment options, as well as information and training
on how they can best manage their illness. National Institute for
Health and Care Excellence (NICE) guidelines for type 2 diabetes
(NICE 2015) recommend that structured education must be in-
tegrated into routine care and should be offered to all. In addition,
the National Health Service (NHS) report on commissioning of
mental health and diabetes services in the UK (NHS Diabetes
2011) states that people with severe mental illness who develop
diabetes should have access to appropriate diabetes care. However,
despite evidence suggesting that diabetes self management pro-
grammes have a positive impact on clinical, lifestyle and psychoso-
cial outcomes (Deakin 2005; Duke 2009; Pal 2013; Steed 2003;
Steinsbekk 2012; Thorpe 2013), it remains unclear whether a di-
agnosis of severe mental illness has an impact on the effectiveness
of such interventions, as people with severe mental illness are not
likely to receive standard diabetes education (Goldberg 2007b).
For people with severe mental illness, physical health may not be
a priority (Buhagiar 2011) and motivation to change may be lim-
ited, presenting additional challenges for successful self manage-
ment. Therefore, it cannot be assumed that the findings reported
in existing systematic reviews of diabetes self management inter-
ventions can be generalised to those with severe mental illness.
Description of the intervention
Diabetes self management interventions are complex, as they con-
sist of several interacting components (Craig 2008). Self manage-
ment refers to an individual’s ability to manage the clinical and
psychosocial consequences, along with the lifestyle changes, in-
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herent in living with a chronic condition (Barlow 2002). On the
basis of this broad definition, the content and complexity of di-
abetes self management interventions vary significantly, not only
in terms of their aims and the behaviour/s they target (e.g. self
monitoring of blood glucose, insulin titration, diet, exercise), but
also in terms of their intensity, duration, place of delivery (i.e. pri-
mary or secondary care), mode of delivery (i.e. group, individual,
online), type and training of the facilitator (i.e. diabetes and/or
mental healthcare professional/s or lay person), active ingredients
within the intervention and theoretical background.
Adverse effects of the intervention
Little evidence suggests that diabetes self management interven-
tions are associated with adverse effects. However, adverse effects
could occur if:
• the content of the diabetes self management intervention is
not evidence-based, potentially resulting in incorrect
information and training for people with type 2 diabetes;
• participants misunderstand the information given or are
unable to perform the required behaviours;
• participants became anxious as a result of being more
engaged, for example, if self monitored blood glucose readings
are high and participants are unable to understand why (Peel
2004);
• being more engaged leads to inappropriate use of healthcare
services;
• exercise leads to injury or increased pain and fatigue; or
• participants make decisions that are detrimental to their
health and well-being, such as insulin titration that leads to
hypoglycaemia.
How the intervention might work
Development of self management interventions has been influ-
enced by several theories of health behaviour change, including
social cognitive theory (Bandura 1986), the theory of reasoned
action and planned behaviour (Ajzen 1991), self regulation the-
ory (Leventhal 1984) and the transtheoretical model (Prochaska
1997). All of these theories identify concepts that predict health
behaviour, with primary focus on beliefs, attitudes and expecta-
tions. Resulting self management interventions differ in their the-
oretical underpinnings and hence in the techniques they adopt to
change behaviour. For example, a diabetes self management in-
tervention based on social cognitive theory (Bandura 1986) may
seek to reduce carbohydrate intake by increasing diet-related self
efficacy. Bandura proposed several ways in which self efficacy can
be enhanced, including skills mastery wherein a person gains con-
fidence by successfully achieving a goal, observation of someone
performing the behaviour and verbal persuasion. These behaviour
change techniques are proposed to be the ’active ingredients’ that
explain how a self management intervention might work.
In addition to the active ingredients, behaviour change interven-
tions involve other key features, including the behaviour or be-
haviours they aim to change (i.e. diet, exercise, self monitoring)
and their duration, intensity, setting and mode of delivery and
type and training of the facilitator, all of which can influence
engagement and the efficacy and replicability of an intervention
(Hoffman 2014). Figure 1 presents a simplified schematic repre-
sentation of the conceptual framework for diabetes self manage-
ment interventions, which acknowledges their complex nature,
alongwith the best-established selfmanagement behaviour change
techniques included in these types of interventions.
7Self management interventions for type 2 diabetes in adult people with severe mental illness (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Schematic representation of diabetes self management.
Why it is important to do this review
Although some evidence indicates statistically and clinically signif-
icant benefits derived fromdiabetes selfmanagement interventions
in the general population (Deakin 2005; Duke 2009; Pal 2013;
Steed 2003; Steinsbekk 2012; Thorpe 2013), little evidence sug-
gests that these interventions are effective in changing outcomes
for people with severe mental illness and type 2 diabetes. A system-
atic review of diabetes self management specifically for those with
schizophrenia or schizoaffective disorder found that approaches
delivered in both inpatient and outpatient settings can be effective
in managing type 2 diabetes, particularly those that address diet
and exercise behaviour, but concluded that intervention packages
need to be tailored to the unique challenges associated with de-
creased cognition and motivation, limited resources and the loss
of energy and weight gain associated with use of antipsychotics
(Cimo 2012). This review aims to broaden the inclusion criteria
of this previous systematic review (Cimo 2012) to severe mental
illnesses other than schizophrenia and schizoaffective disorder and
other outcomes, including patient-reported and socioeconomic
outcomes.
This review will evaluate the effects of diabetes self management
interventions for people with severe mental illness and type 2 dia-
betes, and it will provide us with the opportunity to describe, using
established reporting systems, the active components of these in-
terventions and the theoretical frameworkswithinwhich theywere
developed to establish how they work. Medical Research Council
(MRC) guidelines for developing complex interventions (Craig
2008) and the Consolidated Standards of Reporting Trials (CON-
SORT) statement for randomised controlled trials (RCTs) of non-
pharmacological interventions (Boutron 2008) acknowledge the
need for improved methods of specifying and reporting interven-
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tion content. In response, the Behaviour Change Technique Tax-
onomy (BCTTv1) (Michie 2013) was developed. This taxonomy
provides standardised descriptions of different techniques, so that
a shared language is used in the field of behaviour change, and
links these techniques to published theories of behaviour. This
systematic review will use the BCTTv1 (Michie 2013) to classify
intervention content. Applying this method will help to provide
a cumulative understanding, across the field of behaviour change,
of how diabetes self management interventions change behaviour
and improve outcomes. In addition, we will apply a coding sys-
tem to assess the way in which these interventions have applied
theory (Michie 2010). This theoretical coding system will enable
an assessment of how, and to what extent, theory has been used
to develop the intervention. Use of these coding systems will also
prove helpful in systematically identifying and documenting the
content of diabetes self management interventions for people with
severe mental illness and type 2 diabetes, and will establish which
components and theories are most effective. By undertaking sub-
group analysis, review authors will attempt to identify whether
intervention effects vary not only by intervention characteristics,
but also by participant characteristics, to establish which type of
self management intervention works best, for whom and under
what conditions.
O B J E C T I V E S
To assess the effects of diabetes self management interventions
specifically tailored for adults with type 2 diabetes and severe men-
tal illness.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included only randomised controlled clinical trials (RCTs).
Types of participants
Adults with severe mental illness and type 2 diabetes. We defined
adult participants as those 18 years of age and older. Diagnosis
of type 2 diabetes should have been consistent with the standard
classification criteria valid at the time of the trial (e.g. ADA 1999;
ADA 2008; WHO 1998). We defined severe mental illness as
psychosis, schizophrenia, schizoaffective disorder, bipolar disorder,
personality disorder or depressionwith psychotic features, however
diagnosed.
Types of interventions
Intervention
Interventions were targeted to improve self management of type 2
diabetes mellitus; these could include interventions that targeted,
for example, self monitoring of blood glucose, diet or exercise be-
haviour. Interventions may or may not have included self man-
agement of severe mental illness, but we excluded interventions
that focused solely on the self management of mental health. The
intervention could be of any duration.
Comparator
The comparison group provided another active intervention or
usual/standard care.
Exclusions
Any intervention that:
• included only participants with type 1 diabetes;
• included participants without severe mental illness;
• involved participants younger than 18 years of age,
including trials that included both adults and children;
• was targeted at healthcare professionals; or
• focused exclusively on self management of mental health.
We included trials that recruited participants with both type 1 and
2 diabetes only if we could extract results for participants with type
2 diabetes. We included trials that recruited participants with and
without severe mental illness only if we could extract results for
participants with severe mental illness.
Types of outcome measures
Primary outcomes
• Self care behaviours.
• Diabetes-related complications.
• Adverse events.
Secondary outcomes
• All-cause mortality.
• Health-related quality of life.
• Diabetes knowledge.
• Self efficacy.
• Progression of severe mental illness.
• Glycosylated haemoglobin A1c (HbA1c).
• Body mass index (BMI).
• Weight.
• Blood pressure.
• Change in medication or in intensity of drug treatment.
• Socioeconomic effects.
Methods of outcome measurement
• Self care behaviours: evaluated with a validated instrument
such as the Summary of Diabetes Self care Activities measure
(Toobert 2000).
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• Diabetes-related complications: defined as vascular
complications (angina pectoris, myocardial infarction, stroke or
peripheral vascular disease), neuropathy, nephropathy,
retinopathy, diabetic foot and lower limb amputation and heart
failure.
• Adverse events of the intervention: defined as, for example,
hypoglycaemia, pain, fatigue and anxiety.
• All-cause mortality: defined as death from any cause.
• HbA1c: measured as glycosylated haemoglobin A1c.
• Health-related quality of life: evaluated with a validated
generic or disease-specific instrument, such as Short Form (SF)-
36 (McHorney 1993; Ware 1992) or the Diabetes Health Profile
(Meadows 2000).
• Diabetes knowledge: evaluated with a validated instrument
such as the Brief Diabetes Knowledge Test (Fitzgerald 1998).
• Self efficacy (general or diabetes-specific): evaluated with a
validated instrument such as the Diabetes Empowerment Scale
(Anderson 2000).
• Progression of severe mental illness: assessed by a disease-
specific measure, such as the Positive and Negative Syndrome
Scale (Kay 1987), or by generic measures such as the Clinical
Global Impressions Scale (Busner 2007) or the Health of the
Nation Outcome Scale (Wing 1998).
• BMI: measured as body weight in kilograms per meter
squared (kg/m²).
• Weight: in kilograms or pounds.
• Blood pressure: systolic and diastolic blood pressure in
millimetres of mercury (mmHg).
• Change in medication or intensity of drug treatment:
intensity of type 2 diabetes treatment defined as an increase in
medication dose or the introduction of an additional drug;
intensity of severe mental illness treatment defined as an increase
in medication dose or the introduction of an additional drug.
• Socioeconomic effects: direct costs defined as admission/re-
admission rates, average length of stay, visits to general
practitioner, accident/emergency visits; indirect costs defined as
resources lost as the result of illness of participants or family
members.
Timing of outcome measurement
We classified the timing of outcome measurements as short,
medium and long term. Short-term follow-up was defined as mea-
surement taken within one month of the end of the interven-
tion period, therefore capturing immediate effects of the interven-
tion; medium-term follow-up was defined as between one and six
months post intervention, and long-term follow-up as six months
and longer.
Summary of findings
We present a ’Summary of findings table’ to report the following
outcomes, listed according to priority.
• Diabetes-related complications.
• All-cause mortality.
• Adverse events.
• Health-related quality of life.
• Self care behaviours.
• HbA1c.
• Socioeconomic effects.
Search methods for identification of studies
We planned to search the Allied and Complementary Medicine
Database (AMED) (McBain 2014); however, on the recommenda-
tion of the Cochrane Metabolic and Endocrine Disorders Group
(CMED), we deemed AMED redundant, as it was unlikely to re-
veal any relevant trials above and beyond the included databases.
Electronic searches
We searched the following sources from inception of each database
to the specified date, and we placed no restrictions on the language
of publication.
• Cochrane Library (7 March 2016).
• MEDLINE <1946 to Present> (7 March 2016).
• EMBASE <1974 to 2016 Week 10> (7 March 2016).
• PsycINFO <1806 to March Week 1 2016> (7 March 2016).
• CINAHL (7 March 2016).
• ClinicalTrials.gov (7 March 2016).
• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) Search Portal (http://
apps.who.int/trialsearch/) (7 March 2016).
We continuously applied a MEDLINE (via Ovid SP) email alert
service to identify newly published trials using the same search
strategy as described for MEDLINE (for details on search strate-
gies, see Appendix 1). After supplying the final review draft for
editorial approval, CMED performed a complete update search
on all databases available at the editorial office and sent the results
of this search to the review authors.
Searching other resources
We planned to identify other potentially eligible trials or ancillary
publications by searching the reference lists of retrieved articles, in-
cluding trials, (systematic) reviews, meta-analyses and health tech-
nology assessment reports. We searched unpublished literature by
using the following databases.
• BASE: Bielefeld Academic Research Engine (http://
www.base-search.net/).
• Open Grey (http://www.opengrey.eu/).
• NHS Evidence (http://www.evidence.nhs.uk/).
• UK Clinical Research Network Study Portfolio (http://
public.ukcrn.org.uk/search/).
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Data collection and analysis
Selection of studies
Two review authors (HM, MH) independently scanned the ab-
stract, title or both of every record retrieved. We rejected articles
at this stage if they did not meet the inclusion criteria. If it was
not possible to reject at this point, we retrieved full-text copies
of the article. Two review authors (HM, JJ) then independently
scanned the full text of all remaining articles. We resolved dif-
ferences between review authors by discussing them with the re-
view team and by contacting trial authors for clarification. We in-
cluded an adapted PRISM (Preferred Reporting Items for System-
atic Reviews andMeta-analyses) diagramof trial selection (Liberati
2009).
We present a PRISMA flowchart showing the process of trial se-
lection (Liberati 2009).
Data extraction and management
For trials that fulfilled the inclusion criteria, two review authors
(HM, KM) independently extracted key participant and inter-
vention characteristics and reported data on efficacy outcomes
and adverse events by using standard data extraction templates,
with disagreements resolved by discussion (see Characteristics of
included studies; Appendix 2; Appendix 3; Appendix 4; Appendix
5; Appendix 6; Appendix 7; Appendix 8; Appendix 9).
We presented Information, including trial identifier, about poten-
tially relevant ongoing studies in the Characteristics of ongoing
studies table. We planned to find the protocol of each included
trial and to report primary, secondary and other outcomes in com-
parison with data derived from publications in a joint appendix ti-
tled “Matrix of trial endpoints (publications and trial documents)”
(Appendix 6).
We emailed the authors of all included trials to enquire whether
they would be willing to answer questions regarding their trials.
Appendix 10 shows the results of this survey. We sought relevant
missing information on the trial from the primary author of the
article, when required.
We coded both intervention and comparator groups for their use
of theory and behaviour change techniques.
Use of theory
A theory coding scheme has been developed that assesses how and
to what extent theory has been used to develop an intervention
(Michie 2010). This coding scheme consists of 19 items, each re-
quiring a ’yes’, ’no’ or ’do not know’ response. The scheme classi-
fies these 19 questions into six categories: (1) Is theory mentioned?
(2) Are the relevant theoretical constructs targeted? (3) Is theory
used to select recipients or to tailor an intervention? (4) Are the
relevant theoretical constructs measured? (5) Is theory tested? and
(6) Has theory been refined? For the purposes of any analysis, if
the theoretical basis for the intervention group was the same as
for the control group, we coded the intervention as not having a
theoretical basis (except for descriptive purposes) because theory
was unable to explain the difference in effect size between the two
groups.
Use of behaviour change techniques
We used the Behaviour Change Technique Taxonomy (BCTTv1)
(Michie 2013) to code both intervention and control groups. We
provided appropriate training for those extracting and coding be-
haviour change techniques. If the same behaviour change tech-
nique (BCT) was employed within both intervention and control
groups, we coded the intervention as not containing the BCT (ex-
cept for descriptive purposes) because the BCT would not explain
differences in effect size between the two conditions.
Dealing with duplicate and companion publications
In the event of duplicate publications, companion documents or
multiple reports of a primary trial, we maximised yield of infor-
mation by collating all available data and using the most com-
plete data set aggregated across all known publications. In case of
doubt, we planned to assign priority to the publication reporting
the longest follow-up associated with our primary or secondary
outcomes.
Assessment of risk of bias in included studies
Two review authors (HM, KM) independently assessed risk of bias
for each included trial and resolved disagreements by consensus.
We assessed risk of bias by using the tool of The Cochrane Col-
laboration for assessment of risk of bias (Higgins 2011a; Higgins
2011b) based on the following criteria.
• Random sequence generation (selection bias).
• Allocation concealment (selection bias).
• Blinding of participants and personnel (performance bias).
• Blinding of outcome assessment (detection bias).
• Incomplete outcome data (attrition bias).
• Selective reporting (reporting bias).
• Other potential sources of bias.
We rated risk of bias criteria as ’low risk’, ’high risk’ or ’unclear risk’
and evaluated individual bias items as described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
We presented a ’Risk of bias summary’ figure and assessed the
impact of individual bias domains on trial results at endpoint and
trial levels. In case of high risk of selection bias, we marked all
endpoints investigated in the associated trial as ’high risk’.
For performance bias (blinding of participants and personnel) and
detection bias (blinding of outcome assessors), we evaluated risk of
bias separately for each outcome (Hróbjartsson 2013). We noted
whether outcomes were self reported, investigator assessed or adju-
dicated outcome measures, for example, whether hypoglycaemia
was reported by participants or by trial personnel.
We considered the implications of missing outcome data from
individual participants, such as high drop-out rates (e.g. above
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15%) or disparate attrition rates (e.g. difference of 10% or more
between trial arms).
We assessed outcome reporting bias by integrating the results of
the appendix ’Examination of outcome reporting bias’ (Appendix
7), the appendix ’Matrix of trial endpoints (publications and
trial documents)’ (Appendix 6) and the section ’Outcomes (out-
comes reported in abstract of publication)’ of the Characteristics
of included studies tables. This analysis formed the basis of our
judgement of selective reporting (reporting bias).
We defined the following endpoints as self reported outcomes.
• Health-related quality of life.
• Self care behaviours.
• Diabetes knowledge.
• Self efficacy.
• Adverse events, depending on measurement.
• Body mass index (BMI), depending on measurement.
• Weight, depending on measurement.
• Change in medication or intensity of drug treatment,
depending on measurement.
We defined the following outcomes as investigator-assessed out-
comes.
• HbA1c.
• All-cause mortality.
• Diabetes-related complications.
• BMI, depending on measurement.
• Weight, depending on measurement.
• Blood pressure.
• Change in medication or intensity of drug treatment,
depending on measurement.
• Socioeconomic effects.
Measures of treatment effect
Weplanned to express dichotomous outcomes as risk ratios (RRs),
along with 95% confidence intervals (95% CIs). For continu-
ous outcomes when the same measurement scale was used (e.g.
HbA1c), we measured treatment effects as the difference in mean
changes from baseline. For continuous outcomes with different
measurement scales, such as quality of life, we measured treatment
effects as standardised mean differences (SMDs). The definition
of SMDused in Cochrane reviews is the effect size known in social
science as Hedges’ g (adjusted) (Hedges 1985). If Hedges’ g was
not reported, we calculated it as the difference between the two
means (intervention and control) divided by the pooled standard
deviation. If this was not possible, we planned to describe the re-
sults of each trial in a narrative synthesis. We planned to express
time-to-event data as hazard ratios (HRs) with 95% CIs.
Unit of analysis issues
We planned to take into account the level at which randomisation
occurred, such as cross-over trials, cluster-randomised trials and
multiple observations for the same outcome.Weplanned to extract
data from cross-over trials for intervention and control groups at
baseline and at the time point immediately preceding cross-over.
In case of a unit of analysis error in cluster-RCTs, we planned
to adjust for the design effect by reducing the size of the trial to
its “effective sample size” (Rao 1992). We would have calculated
this by dividing the original sample size by the ’design effect’. The
design effect is 1 + (M - 1) * ICC, where M is the average cluster
size, and ICC is the intra-cluster correlation coefficient. For di-
chotomous data, we planned to divide the number of participants
and the number experiencing the event by the design effect. For
continuous data, we planned to reduce only sample sizes, leaving
means and standard deviations unchanged (Higgins 2011a).
Dealing with missing data
We attempted to obtain missing data from trial authors and
carefully evaluated important numerical data such as screened,
randomised participants, as well as intention-to-treat, as-treated
and per-protocol populations. We investigated attrition rates (e.g.
drop-outs, losses to follow-up, withdrawals) and we critically ap-
praised issues of missing data and use of imputation methods
(e.g. last observation carried forward, mean imputation, imputing
based on predicted values from a regression analysis).
When standard deviations for outcomes were not reported and
we did not receive the information from trial authors, we planned
to impute these values by assuming the standard deviation of the
missing outcome to be the average of standard deviations from
those trials for which this information was reported. We planned
to investigate the impact of imputation on meta-analyses by per-
forming sensitivity analysis.
When trial authors failed to respond within one month of the first
contact, we made a second attempt. If we received no response
after two months, we recorded data as missing.
Assessment of heterogeneity
In the event of substantial clinical or methodological heterogene-
ity, we would not report trial results as the pooled effect estimate
in a meta-analysis. We planned to identify heterogeneity (incon-
sistency) by visually inspecting forest plots and by using a stan-
dard Chi² test with a significance level of α = 0.1. In view of the
low power of this test, we also planned to consider the I² statis-
tic, which quantifies inconsistency across trials, to assess the im-
pact of heterogeneity on themeta-analysis (Higgins 2002; Higgins
2003); an I² statistic of 75% or more indicates a considerable level
of heterogeneity (Higgins 2011a). We expected type of diabetes
treatment (i.e. insulin-dependent vs non-insulin-dependent type
2 diabetes) and a diagnosis of severe mental illness to introduce
clinical heterogeneity.
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Assessment of reporting biases
If we had included 10 or more trials that had investigated a partic-
ular outcome, we planned to use funnel plots to assess small-study
effects. Several explanations can be offered for the asymmetry of
a funnel plot, including true heterogeneity of effect with respect
to trial size, poor methodological design (and hence bias of small
trials) and publication bias. We therefore planned to interpret re-
sults carefully (Sterne 2011).
Data synthesis
Unless good evidence suggested homogeneous effects across trials,
we planned to summarise primarily ’low risk of bias’ data by using
a random-effects model (Wood 2008). We planned to interpret
random-effects meta-analyses with due consideration of the whole
distribution of effects and to present a prediction interval (Higgins
2009). A prediction interval specifies a predicted range for the true
treatment effect in an individual trial (Riley 2011).We planned to
perform statistical analyses according to the statistical guidelines
provided in the Cochrane Handbook for Systematic Reviews of In-
terventions (Higgins 2011a).
Quality of evidence
We presented overall quality of the evidence for each outcome
according to the Grading of Recommendations Assessment, De-
velopment and Evaluation (GRADE) approach, which takes into
account issues related not only to internal validity (risk of bias, in-
consistency, imprecision, publication bias) but also to external va-
lidity, such as directness of results.Two review authors (HM, KM)
independently rated the quality of evidence for each outcome. We
present a summary of the evidence in Summary of findings for the
main comparison, which provides key information about the best
estimate of the magnitude of effect, in relative terms and absolute
differences for each relevant comparison of alternative manage-
ment strategies, numbers of participants and trials addressing each
important outcome and the rating of overall confidence in effect
estimates for each outcome. We created Summary of findings for
the main comparison on the basis of methods described in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011a).We presented results on outcomes in the Types of outcome
measures section. Meta-analysis was not possible; therefore, we
presented results in a narrative Summary of findings for the main
comparison.
In addition, we established an appendix titled ’Checklist to aid
consistency and reproducibility of GRADE assessments’ (Meader
2014) (Appendix 11) to help with standardisation of Summary of
findings for the main comparison.
Subgroup analysis and investigation of heterogeneity
Clearly the efficacy of diabetes self management for people with se-
vere mental illness is important, but it is also important to identify
optimal content and delivery methods, as well as participant char-
acteristics, that lead to the most improved outcomes. We planned
to perform subgroup analyses to establish whether intervention
effects varied with different participant populations or interven-
tion characteristics. We used these comparisons only to generate
hypotheses.
We expected the following characteristics to introduce clinical het-
erogeneity, and we planned to carry out subgroup analyses to in-
vestigate interactions.
• Age.
• Gender.
• Disease duration of both type 2 diabetes and severe mental
illness at baseline.
• Insulin-treated versus non-insulin-treated type 2 diabetes.
• Severe mental illness treatment (i.e. antipsychotic
medication vs no antipsychotic medication, typical (first-
generation) vs atypical (second-generation) antipsychotic
medication, olanzapine or clozapine treatment vs other
antipsychotic treatment).
• Diagnosis of severe mental illness (i.e. psychosis,
schizophrenia, schizoaffective disorder, bipolar disorder,
personality disorder or depression with psychotic features).
• Targeted behaviour (e.g. self monitoring, self titration of
drug/insulin, exercise, diet).
• HbA1c at baseline.
• Behaviour change techniques used.
• Use of a theory to inform the intervention.
• Intensity of the intervention provided.
• Intervention setting (i.e. primary or secondary care or
community).
Sensitivity analysis
We planned to perform sensitivity analyses to explore the influ-
ence of the following factors (when applicable) on effect sizes by
restricting analysis to the following.
• Published trials.
• Taking into account risk of bias, as specified in the
Assessment of risk of bias in included studies section.
• Very long or large trials to establish the extent to which they
dominate the results.
• Trials using the following filters: diagnostic criteria,
imputation, language of publication, source of funding (industry
vs other) or country.
We also planned to test the robustness of our results by repeating
the analysis using different measures of effect size (RR, odds ratio
(OR), etc.) and different statistical models (fixed-effect and ran-
dom-effects models).
R E S U L T S
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Description of studies
For a detailed description of trials, see Table 1, Characteristics
of included studies’, ’Characteristics of excluded studies, and ’
Characteristics of ongoing studies’ sections.
Results of the search
After removal of duplicates, the search of 11 electronic biblio-
graphic databases yielded a total of 3080 citations. HM and MH
performed independent screening of the abstracts of these articles,
and CF resolved disagreements. We retrieved full papers for all
abstracts that the reviewers could not confidently exclude. HM
and JJ assessed 60 full-text articles for eligibility. One trial (three
reports) and nine ongoing trials fulfilled the inclusion criteria. We
summarised our search results in Figure 2.
14Self management interventions for type 2 diabetes in adult people with severe mental illness (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 2. Study flow diagram.
Included studies
We included one trial (three trial reports) with 64 participants. We
presented a detailed description of the characteristics of this trial
elsewhere (see Characteristics of included studies). Nine additional
trials were ongoing and provided no published data; we presented
details of these trials in theCharacteristics of ongoing studies table.
Source of data
Weobtained the data presented in this review from three published
articles and through correspondence with the trial author.
Comparisons
The trial was a randomised controlled trial comparing Diabetes
Awareness and Rehabilitation Training (DART) with usual care
plus information (UCI).
Overview of trialpopulations
Investigators approached a total of 77 patients to participate in the
trial; 11 declined to take part and two were already participating
in other psychoeducational or medication trials. A total of 64 par-
ticipants provided consent to participate in the trial - 32 in each
arm. Two did not complete the trial because of inpatient hospi-
talisation, one was unable to complete the follow-up assessment,
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one relocated, one died before receiving the intervention, one had
psychiatric decompensation and one lost interest. Researchers re-
ported results for 57 participants (29 in the control arm and 28
in the intervention arm) immediately post intervention (i.e. six
months from the time of entry into the trial; known as ’short-term
follow-up’) and for 52 participants (26 in each arm) at six months
post intervention (i.e. 12 months from entry into the trial; known
as ’long-term follow-up’). Five other participants were lost to long-
term follow-up, as they had moved out of the area.
Trial design
Investigators conducted the RCT at a single site. They did not re-
port the time frame in which the trial was completed, nor whether
blinding of participants or personnel to group allocation was un-
dertaken. The trial did not include a run-in period, nor was it
terminated early. A trained interviewer, masked to group alloca-
tion, conducted a 90-minute interview to collect trial outcomes.
However, measures taken during this interview remain unclear.
Settings
Investigators conducted the trial in the San Diego healthcare sys-
tem and did not report the site of recruitment.
Participants
Participants were primarily women (65%). The RCT included
only adults over 40 years of age, with a mean age of 54 years. Most
individuals in the sample were white (61%) and were living in
board-of-care facilities (83%). Average length of education was 12
years. The sample consisted of 46 participants with schizophrenia
and nine with schizoaffective disorder. The mean age of partici-
pants at onset of psychiatric illness was 28 years. The mean du-
ration of diabetes was nine years. Trial authors did not report the
presence of co-morbidities. Most participants were receiving oral
treatment (68%) for their diabetes; 12% controlled their diabetes
through dietary changes only, 7% with insulin and 9% with a
combination of an oral agent and insulin. Medical treatment for
their psychiatric illness consisted predominantly of risperidone or
quetiapine (47%); remaining participants received aripiprazole or
ziprasidone (23%), clozapine or olanzapine (30%).
Scores of psychiatric symptom severity, measured on the Positive
and Negative Syndrome Scale (PANSS), indicated a mean positive
symptom score of 14, a negative symptom score of 5 and a general
symptoms score of 4. The mean baseline score on the Hamilton
Depression Scale was 14 and on theMattis Dementia Rating Scale
128.
Mean glycosylated haemoglobin A1c (HbA1c) of participants at
baseline was 7%, body mass index (BMI) was 33 kg/m²and on
average, participants weighed 217 lbs; their mean systolic blood
pressure was 133 mmHg and mean diastolic blood pressure 84
mmHg.
Diagnosis
Although providers confirmed the diagnosis, they did not report
the clinical diagnostic criteria used to identify type 2 diabetes or
severe mental illness. .
Intervention
TheDART intervention was a group-based, face-to-face, 24-week
selfmanagement programme. The intervention took place weekly,
and each session lasted for 90 minutes. DART comprised three
modules: (1) basic diabetes education (sessions one to four, re-
peated at sessions 13 to 16); (2) nutrition (sessions five to eight,
repeated at sessions 17 to 20); and (3) lifestyle exercise (sessions 9
to 12, repeated at sessions 21 to 24). Each module contained four
90-minute manualised sessions. Basic diabetes education included
an explanation of motivation and a review of blood sugar and
symptoms of low and high blood sugar levels, diabetes complica-
tions, how to use a glucose meter, how to talk with your doctor and
types of medication available for treatment. Nutrition education
included a review of food groups, portion sizes, healthy meals and
food labels, along with ways to replace sugar with fat and fibre.
Lifestyle and exercise sessions presented different types of exercise,
as well as their impact on blood sugar levels, use of a pedometer
to track exercise and care of the foot during exercise.
Personnel adapted educational materials for people of middle age
and older with schizophrenia or schizoaffective disorder by intro-
ducing one or two topics per session, providing an overview and
summary of the materials, implementing a teach and query train-
ing method and using mnemonic aids and print materials with
larger font and limited text. They provided participants with sim-
ple guidelines about how they might lead a healthier lifestyle, such
as switching from regular soda or fruit punch to diet soda or water.
One diabetes-trained mental health professional delivered the in-
tervention. Thus facilitators did not make contact with partici-
pants’ healthcare provider during the intervention but encouraged
participants to speak to their physician about their diabetes and
provided guidance on how to record laboratory results and exam-
ination findings.
Trial reports state that the intervention was based on social cog-
nitive theory but provide no other details on how and to what
extent theory was used to develop the intervention. As a result,
the trial scored only one point on a scale of 0 to 8, on the basis
of the theory coding scheme (Michie 2010). Trial authors stated
that they employed the following behavioural change strategies
within the intervention: self monitoring (e.g. pedometers, weekly
weigh-ins), modelling, practice (i.e. healthy food sampling), goal
setting and reinforcement for attendance and behavioural change
(i.e. raffle tickets for small health-related prizes). Through inde-
pendent coding of intervention descriptions, HM and KM used
the Behaviour Change Technique Taxonomy (BCTTv1) (Michie
2013) to identify 14 behaviour change techniques in the interven-
tion arm: self monitoring outcome(s) of the behaviour; social sup-
port (unspecified); material reward (behaviour); behaviour substi-
tution; graded tasks; instruction on how to perform the behaviour;
credible source; feedback on outcome(s) of the behaviour; objects
added to the environment; self monitoring of behaviour; body
changes; behavioural practice/rehearsal; demonstration of the be-
haviour; and goal setting (outcome).
Comparator
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The comparator - usual care plus Information (UCI) - consisted of
usual care provided by participants’ providers and three brochures
provided by the American Diabetes Association that were rele-
vant to diabetes management (i.e. basic diabetes education, nutri-
tion, exercise). Researchers did not specify the theoretical under-
pinnings of the control arm, hence a score of zero on the theory
coding scheme (Michie 2010) and independent coding identified
only one reported BCT: social support (unspecified).
Outcomes
Trial authors did not specify a primary outcome; they measured
a range of outcomes as part of the trial and reported different
outcomes at each follow-up. They provided short-term follow-up
immediately post intervention (i.e. six months from baseline) and
long-term follow-up six months after completion of the interven-
tion (i.e. 12months from baseline). See Appendix 8 and Appendix
9.
Investigators assessed the short-term efficacy of the intervention
in accordance with self care behaviours (total energy expenditure,
total activity, total kilocalories consumed and total minutes of ac-
tivity), weight, BMI, waist circumference, blood pressure, changes
to diabetes and antipsychotic treatment, fasting blood glucose,
HbA1c, cholesterol, lipoprotein, triglycerides, diabetes knowledge
and self efficacy. A total of 57 participants contributed to the analy-
sis of these outcomemeasures. At long-term follow-up, researchers
explored differences between groups across 52 participants, for
BMI, changes to diabetes and antipsychotic medication, weight,
waist circumference, HbA1c, diabetes knowledge and energy ex-
penditure.
To measure dietary intake, investigators asked participants to rank
how often they consumed 70 different foods over the past month
on the Block Brief 2000 Revision of the Health and Habits and
History Questionnaire (Block 1990). They measured physical ac-
tivity by using the Yale Physical Activity Scale (YPAS; Dipietro
1993), which provides two indices: total energy expenditure (TEE)
and total activity summary index (TASI). Researchers calculated
the TEE by using an activities checklist to assess time spent in
various activities during a typical week in the past month. They
calculated the TASI by summing the hours spent in different types
of activities weighted by their intensity. They derived the total
number of minutes of moderate and vigorous activity from each
day of monitoring (i.e. at least three days of data, 10 hours per
day) by using an accelerometer and averaged these values across
the three days.
Trial authors measured diabetes knowledge on the 23-item Dia-
betes Knowledge Test (Fitzgerald 1998) and self efficacy on the
28-item Diabetes Empowerment Scale (Anderson 2000), which
consists of three subscales: managing psychosocial aspects of dia-
betes (MPAD), dissatisfaction and readiness for change (DRFC)
and setting and achieving diabetes goals (SADG).
Investigators measured positive and negative symptoms by using
the Positive and Negative Syndrome Scale (PANSS) (Kay 1987),
depressive symptom severity by using the Hamilton Depression
Rating Scale (HAM-D) (Hamilton 1960) and cognitive function-
ing by using the Dementia Rating Scale (DRS) (Mattis 1973).
They assessed these measures only at baseline to describe the sam-
ple and used the PANSS immediately following the intervention
to explore its effect as a moderator of intervention effectiveness
(McKibbin 2010).
Excluded studies
After evaluation of full texts, we excluded 48 articles from the re-
view. Of these, six were not RCTs; in 34 papers, included partic-
ipants did not meet our definition of severe mental illness (psy-
chosis, schizophrenia, schizoaffective disorder, bipolar disorder,
personality disorder or depression with psychotic features); in four
papers, participants were not solely those diagnosed with type 2
diabetes and data could not be extracted for type 2 participants
only; and in the final four papers, researchers did not evaluate a
diabetes self management intervention.
Risk of bias in included studies
For details on risk of bias of included trials, see Characteristics of
included studies. For an overview of review authors’ judgements
about each risk of bias item for individual trials, see Figure 3.Over-
all, risk of bias was unclear for most aspects, as articles provided
insufficient details for review authors to make an assessment.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
trial.
Allocation
Researchers reported no information on allocation concealment
or method of randomisation; therefore, risk of selection bias was
unclear.
Blinding
Blinding of participants and intervention facilitators would not
have been possible, and trial authors did not report blinding of
other trial personal to group allocation; hence, we classified this
trial as having unclear risk of performance and detection bias. A
blinded trained interviewer undertook a 90-minute interviewwith
each participant to collect data, but trial authors failed to specify
which outcomes were measured by this interview.
Incomplete outcome data
Trial authors did not perform intention-to-treat (ITT) analyses,
and they reported no information on how missing data were
treated. From baseline to immediately post intervention, 11% of
the overall sample, and from baseline to six months post inter-
vention 19%, failed to complete both baseline and follow-up as-
sessments. Researchers did not report reasons for drop-out by trial
arm.
Selective reporting
We judged risk of reporting bias as high. We were unable to find
a published protocol for the trial. The article reporting long-term
outcomes failed to present results for several of the outcomes mea-
18Self management interventions for type 2 diabetes in adult people with severe mental illness (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
sured at short-term follow-up, including blood pressure, fasting
blood glucose, cholesterol, lipoprotein, triglycerides, self efficacy,
total activity, total kilocalories consumed and total minutes of ac-
tivity.
Other potential sources of bias
We identified no other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison
See Summary of findings for the main comparison for the main
patient-relevant outcomes.
Baseline characteristics
For details of baseline characteristics, see Appendix 3, Appendix 4
and Appendix 5.
Diabetes Awareness and Rehabilitation Training
(DART) programme versus usual care plus
information (UCI)
Primary outcomes
Self care behaviours
Trial investigators measured physical activity by using the Yale
Physical Activity Scale (Dipietro 1993). The TEE subscale did not
improve with the DART programme in comparison with UCI
at short-term or long-term follow-up. The TASI improved im-
mediately following the DART programme in comparison with
UCI. Researchers observed no substantial difference in the total
number of minutes of daily activity performed by participants be-
tween DART and UCI at short-term follow-up. The mean en-
ergy expenditure six months after completion of the intervention
was 2148 kcal for the DART group and 2800 kcal for the UCI
group. Trial authors reported that the difference of 652 kcal did
not reflect an improvement. For measurement of dietary intake,
participants completed the Brief 2000 Revision of the Health and
Habits and History Questionnaire (Block 1990), which estimates
the total calories consumed in kilocalories. Participation in the
DART programme did not result in improvement in the num-
ber of calories consumed at short-term follow-up compared with
UCI. Trial authors did not report effects at long-term follow-up
for the TASI, minutes of daily activity or dietary intake.
This trial did not measure or report outcomes in relation to dia-
betes-related complications and adverse events.
Secondary outcomes
This trial did not measure or report outcomes in relation to all-
cause mortality, health-related quality of life nor socioeco-
nomic effects. Although investigators measured positive and neg-
ative affect and depression at baseline, they did not use these scales
to measure progression of mental health across the trial period.
Diabetes knowledge
Diabetes knowledge, as measured by the Diabetes Knowledge Test
(Fitzgerald 1998), improved following completion of the DART
programme comparedwithUCI at both short-term and long-term
follow-up.
Self efficacy
Trial authors assessed self efficacy by using the Diabetes Empow-
erment Scale (Anderson 2000). Scores on all three subscales im-
proved immediately after completion of the DART programme
in comparison with UCI. Trial authors did not report results at
long-term follow-up.
Glycaemic control
Glycaemic control, as measured byHbA1c, showed no statistically
significant effect of the DART programme in comparison with
UCI at short-term (mean difference (MD) 0.6%) or long-term
follow-up (end of trial values 7.9% for DART vs 6.9% for UCI).
Also, fasting blood glucose levels showed no marked differences
between intervention and comparator groups, and this outcome
was reported only at short-term follow-up.
Body mass index (BMI)
Researchers observed improvement in favour of DART in BMI
at short-term (MD 1.7 units) and long-term follow-up (MD 2.4
units).
Weight
Weight improved immediately following completion of the inter-
vention compared with UCI. Although trial authors reported that
participants in the DART group experienced weight loss at long-
term follow-up and UCI participants gained weight, they did not
provide pre-post data.
Blood pressure
Both systolic blood pressure and diastolic blood pressure failed to
improve at short-term follow-up in the DART programme com-
pared with UCI.
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Change in medication or intensity of drug treatment
Trial authors reported few changes in antipsychotic and diabetes
treatment type in the short term or over the long term. Groups
were also similar in terms of antipsychotic and diabetes treatment
type at both follow-up intervals. Investigators reported no data for
either of these outcomes.
Other outcomes
We did not specify several other secondary outcomes in our pro-
tocol, but trial authors included them in the trial and reported
that they showed an effect for the intervention. Waist circum-
ference in inches improved as a result of the DART programme
compared with UCI, both at short-term and long-term follow-up.
Researchers presented short-term effects for triglycerides but no
substantial short-term effects on levels of cholesterol in the DART
programme in comparison with UCI, or for high-density or low-
density lipoproteins.
Subgroup analyses
Trial authors explored the moderating effects of schizophrenia
symptoms following the intervention, as measured by the PANSS
(Kay 1987), on changes in diabetes knowledge and self efficacy
frombaseline to short-term follow-up. These results indicated that
differences in changes in diabetes knowledge between the DART
programme andUCI were dependent on the prevalence and sever-
ity of schizophrenia symptoms. When the total psychiatric symp-
tom severity score was low at baseline, change in diabetes knowl-
edge was greater in the DART group than in the UCI group at
short-term follow-up. However, when the total psychiatric symp-
tom severity score was high at baseline, investigators reported no
difference in the change in diabetes knowledge between the two
groups at short-term follow-up. They observed interaction effects
for both negative and general symptom scores on the PANSS (Kay
1987). When negative or general symptom scores were low at
baseline, the DART group performed better in relation to their
diabetes knowledge than the UCI group. However, when negative
or general scores were high, trial authors reported no differences
between the two arms. Positive symptom severity did not interact
with trial arm on any of the three self efficacy subscales.
Sensitivity analyses
We performed no sensitivity analyses because of the limited num-
ber of trials included in the review (n = 1).
Assessment of reporting bias
We did not draw funnel plots because the number of included
trials was limited (n = 1).
Ongoing studies
We found nine ongoing RCTs, seven in progress in the USA, one
in Germany and another in Canada. In seven trials, inclusion cri-
teria included type 2 diabetes and at least one of the included
severe mental illnesses. Hence, these trials would be included in
subsequent updates of this review only if suitable subgroup anal-
yses were performed.
D I S C U S S I O N
Summary of main results
Effects of the intervention on clinical outcomes
We included one trial involving 64 participants with type 2 di-
abetes and either schizophrenia or schizoaffective disorder. This
randomised controlled trial (RCT) compared the 24-week Dia-
betes Awareness and Rehabilitation Training (DART) programme
- a group-based face-to-face self management intervention cover-
ing general diabetes education, nutrition and exercise - with usual
care plus information (UCI). Most individuals in the sample were
women (65%), and the mean age of participants was 54 years.
The mean age of onset of psychiatric illness was 28 years, and the
mean duration of diabetes nine years. Investigators recorded out-
comemeasures immediately following the intervention (i.e. short-
term follow-up) and six months post intervention (i.e. long-term
follow-up).
Trial authors observed no substantial effects on glycaemic con-
trol, blood pressure, cholesterol, high and low lipoprotein or total
number of minutes of activity per day. They reported observable
improvements in body mass index (BMI) and waist circumference
at short-term and long-term follow-up in the DART programme
compared with UCI, and in triglycerides and weight immediately
post intervention only.
Effects of the intervention on patient-reported
outcomes
Diabetes knowledge, self efficacy and total activity levels of par-
ticipants improved immediately following the DART programme
in comparison with UCI. Participants maintained improvements
in diabetes knowledge at long-term follow-up. Total calories con-
sumed by participants and their total energy expenditure failed to
improve as a consequence of the programme in comparison with
usual care.
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Behaviour change techniques used in the intervention
and mechanisms of action
Trial authors did not specify how and to what extent theory had
been used to develop the content for the intervention or control
group. Coding of DART revealed 13 behaviour change techniques
unique to the DART programme.
Overall completeness and applicability of
evidence
The primary limitation of this review is the overall lack of trials.
We identified only one RCT with 64 participants that met the
inclusion criteria. This RCT targeted only older adults (40+ years)
with schizophrenia or schizoaffective disorder; we found no suit-
able trials that recruited younger participants or those with other
severe mental illnesses. Another significant limitation was lack of
measurement and reporting of outcome measures specified in the
protocol. The includedRCTdid notmeasure or report findings on
adverse events, diabetes-related complications, mortality, health-
related quality of life, progression of mental health nor socioe-
conomic effects. Although the intervention was reported to be
grounded in social cognitive theory, trial authors presented no in-
formation on how and to what extent social cognitive theory had
been used to develop the DART programme. Subgroup analysis
to explore the effects on intervention effectiveness of participant
and intervention characteristics, such as active ingredients, was not
possible.
Quality of the evidence
We rated the quality of the only trial included in this review as very
low. Researchers did not measure outcomes related to diabetes-
related complications, all-cause mortality, adverse events, health-
related quality of life and socioeconomic effects. Trial authors did
not provide details about the randomisation process. The nature of
the intervention precluded participant blinding, and it was unclear
whether personnel or outcome assessors were blinded to group
allocation. Investigators defined self care behaviour in terms of
physical activity and food consumption. Whilst some of these
measures were objective, such as total minutes of physical activity
measured by an accelerometer, the remainder involved subjective
reports.
We noted selective reporting bias in relation to weight, blood pres-
sure, fasting blood glucose, cholesterol, high-density and low-den-
sity lipoproteins, triglycerides, self efficacy and several self care
behaviours. Although researchers reported the effects of the in-
tervention at short-term follow-up for these outcomes, they did
not report long-term effects, possibly indicating that these analy-
ses were not statistically significant and hence were not reported.
In addition, investigators did not explore the moderating effects
of symptoms in relation to self care behaviours nor glycosylated
haemoglobin (HbA1c). The small sample size and the number of
included trials significantly reduced the precision of this review.
Potential biases in the review process
This Cochrane review addresses a specific and well-defined re-
search question. The search of the literature was extensive and sen-
sitive, but publication bias remains a possibility. The final review
includes only English language articles, although we did not limit
our search criteria to publications in English.
Although the inclusion criteria were clearly defined, we noted con-
tinued ambiguity in the wider literature on the definition of dia-
betes self management. We deliberately kept this definition broad,
so as not to exclude potentially important interventions, as long
as the primary focus of the intervention was to enable participants
to better manage their type 2 diabetes; however, as a result of often
brief descriptions, we based judgements about inclusion on lim-
ited data.
Selection of trials followed the protocol and different review au-
thors were responsible for selecting trials at each stage of the re-
view, which may have introduced bias into the selection process.
However, we ensured that one review author was involved at all
stages to maintain some consistency .
We excluded trials in which the sample combined individuals with
type 1 and type 2 diabetes, or those who had been diagnosed with a
severe mental illness not listed in our inclusion criteria if subgroup
analyses had not been performed; hence important and relevant
data may be missing from this review.
We made the decision to include all three articles reporting one
RCT, tomaximise the quantity of data available for this review.We
did not treat these three articles as three individual trials because
each article described different aims. We have emphasised this fact
throughout the review, and awareness of this is important when
the findings and conclusions of this review are considered.
Agreements and disagreements with other
studies or reviews
A review of effective lifestyle interventions for improving type 2 di-
abetes self management in people with schizophrenia or schizoaf-
fective disorder by Cimo 2012 reported reductions in weight and
BMI, but limited evidence for improved glycaemic control. Our
review supports these findings. Cimo 2012 concluded that lifestyle
interventions can be effective in management of type 2 diabetes,
particularly when the intervention incorporates diet and exercise
components. However, the review includes only four papers - two
were short-term and long-term follow-up articles reported in this
systematic review (McKibbin 2006; McKibbin 2010), and two
were quasi-experimental trials. Hence these conclusions may be
overestimated. Consistent with this review, Cimo 2012 recom-
mended that future research should focus on the long-term sus-
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tainability of diabetes self management interventions for people
with severemental illness, and on addressing the needs of a younger
population.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Evidence is insufficient to show whether type 2 diabetes self man-
agement interventions for people with severe mental illness are
effective in improving clinical, psychosocial, behavioural or eco-
nomic outcomes.
Implications for research
The small number of published trials reveals a significant gap in
the literature for theory- and evidence-based interventions that
enable service users with severe mental illness to manage their
type 2 diabetes. Several ongoing trials may meet the inclusion
criteria in future updates of this review. However, the inclusion
criteria formost of these ongoing trials include but are not exclusive
to type 2 diabetes and severe mental illness, and therefore will
contribute to the objectives of this review only if subgroup analyses
are performed for this subset of participants.
We therefore recommend that theory- and evidence-based in-
terventions should be developed that address the specific chal-
lenges experienced by people with severe mental illness when they
attempt to manage their diabetes, and that these interventions
should be evaluated in robust randomised controlled trials. Fu-
ture publications should ensure that the theoretical basis, active
ingredients (behaviour change techniques) and doses of these in-
gredients (frequency of behaviour change techniques) are clearly
described in published protocols and final reports. This will lead
to a better understanding of which elements of an intervention
are the most effective components for changing diabetes-related
behaviours and outcomes.
Finally, we affirmed a clear need to establish whether these inter-
ventions have effects on all-cause mortality, health-related quality
of life and socioeconomic aspects, or whether they lead to adverse
events, such as hypoglycaemic events or diabetes-related compli-
cations.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
McKibbin 2010
Methods Parallel randomised controlled clinical trial
Superiority design
Participants Inclusion criteria
• Age 40 or older
• Physician-confirmed diagnoses of schizophrenia
• Physician-confirmed diagnoses of diabetes mellitus
• Ambulatory physician approval to participate in lifestyle exercise
Exclusion criteria
• Inability to complete the assessment battery
• Physician-confirmed diagnosis of congestive heart failure
Diagnostic criteria: -
Interventions Number of study centres: -
Treatment before study: -
Intervention: Diabetes Awareness and Rehabilitation Training (DART), a 24-week
group-based intervention, consisting of weekly 90-minute sessions. Covers basic educa-
tion, nutrition and exercise
Control: Usual care plus information (UCI) condition consisted of usual care provided
by participants’ physicians and three brochures provided by the American Diabetes
Association relevant to diabetes management (i.e. basic diabetes education, nutrition
and exercise)
Provider: 1 diabetes-trained mental health professional
Outcomes Outcomes reported in abstract of publication
• Diabetes knowledge
• Self efficacy
• Symptoms
Outcomes reported in abstract of publication (McKibbin 2006)
• BMI
• Blood pressure
• Fasting blood glucose
• Accelerometry
• Triglycerides
• Diabetes knowledge
• Diabetes self efficacy
• Physical activity
• HbA1c
Outcomes reported in abstract of publication (McKibbin 2010)
• BMI
• Waist circumference
• Diabetes knowledge
• HbA1c
• Energy expenditure
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McKibbin 2010 (Continued)
Study details Run-in period: -
Trial terminated before regular end: no
Publication details Language of publication: English
Funding: Betty Irene Moore Foundation and National Institute of Nursing Re-
search; National Insititute of Mental Health grants and Department of Veterans Affairs
(McKibbin 2006); National Institute for Mental Health and National Center for Re-
search Resourses (McKibbin 2010)
Publication status: peer-reviewed journal
Stated aim for study Quote from publication: “To explore the relationship between the symptoms of
schizophrenia experienced by older persons diagnosed with schizophrenia and type 2
diabetes mellitus and their response to a health promoting intervention”
Quote from publication (McKibbin 2006): “To test the efficacy of a novel, manualised
24-week lifestyle intervention to reduce obesity in middle-aged and older persons with
schizophrenia and type-2 DM”
Quote from publication (McKibbin 2010): “To test the sustained impact of a 6-month
diabetes management intervention in middle-aged and older adults with schizophrenia
and type 2 diabetes mellitus”
Notes Long-term follow-up of McKibbin 2006 and Leutwyler 2010 (see McKibbin 2006)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quote from publication: “The total sam-
ple was composed of 64 subjects from
board and care, day treatment programs,
and community clubhouses that were ran-
domly assigned to treatment (DART) and
control groups (UCI)”
Comment: method of randomisation not
reported
Allocation concealment (selection bias) Unclear risk Comment: insufficient evidence to permit
judgement
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: insufficient evidence to permit
judgement
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: insufficient evidence to permit
judgement
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Comment: insufficient evidence to permit
judgement
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McKibbin 2010 (Continued)
Selective reporting (reporting bias) High risk Comment: the paper does not report on
outcomes related to progression of se-
vere mental illness, change in medica-
tions, bloodpressure, fasting blood glucose,
cholesterol, lipoprotein, triglycerides, self
efficacy, total activity, total kilocalories or
total minutes of activity, despite evidence
indicating that these outcomes were mea-
sured
Comment Leutwyler 2010 (see McKibbin
2006): this paper reports only on outcomes
related to knowledge and self efficacy; sev-
eral other outcomes were measured
Comment McKibbin 2006: this paper
does not report on outcomes related to pro-
gression of severe mental illness or change
inmedications, despite evidence indicating
that these outcomes were measured
Other bias Low risk Comment: nothing detected
“-” denotes not reported
BMI: body mass index; DART: Diabetes Awareness and Rehabilitation Training; HbA1c: glycosylated haemoglobin A1c; UCI: usual
care plus information
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ACTRN12614000138684 Not a randomised controlled trial (RCT)
Bogner 2010 Not a severe mental illness
Bogner 2012 Not a severe mental illness
Ell 2009 Not a severe mental illness
Gois 2009 Not a severe mental illness
Green 2015 Includes type 1 and type 2 diabetes
Hjorth 2014 Includes type 1 and type 2 diabetes
Huang 2002 Not a severe mental illness
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(Continued)
Huang 2004 Not a severe mental illness
ISRCTN13762819 Not a diabetes self management intervention
Katon 2004 Not a severe mental illness
Katon 2006 Not a severe mental illness
Katon 2008 Not a severe mental illness
Katon 2012 Not a severe mental illness
Lamers 2011 Not a severe mental illness
Lustman 1998a Not a severe mental illness
Lustman 1998b Not a severe mental illness
NCT00253240 Not a randomised controlled trial (RCT)
NCT00468676 Not a severe mental illness
NCT00564070 Not a severe mental illness
NCT00627029 Not a severe mental illness and not a diabetes self management intervention
NCT01098253 Not a severe mental illness
NCT01106885 Not a severe mental illness
NCT01228032 Not a diabetes self management intervention
NCT01890226 Not a diabetes self management intervention
NCT02027259 Not a severe mental illness
NCT02029989 Not a diabetes self management intervention
NCT02053714 Not a randomised controlled trial (RCT)
NCT02160639 Not a severe mental illness
Nelson 2014 Not a severe mental illness
Petrak 2013 Not a severe mental illness
Pibernick-Okanovic 2009 Not a severe mental illness
Piette 2011a Not a severe mental illness
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(Continued)
Piette 2011b Not a severe mental illness
Robinson 2010 Not a randomised controlled trial (RCT)
Safren 2014 Not a severe mental illness
Sajatovic 2011 Not a randomised controlled trial (RCT)
Salisbury 2014 Not a diabetes self management intervention
Schneider 2011 Not a severe mental illness
Simon 2007 Not a severe mental illness
Spencer 2013 Not a severe mental illness
Stiefel 2008 Not a severe mental illness
Taveira 2011 Includes type 1 and type 2 diabetes
van Bastelaar 2009 Not a severe mental illness
van Bastelaar 2011a Not a severe mental illness
van Bastelaar 2011b Not a severe mental illness
van Bastelaar 2012 Not a severe mental illness
van Dijk 2013 Not a severe mental illness
Characteristics of ongoing studies [ordered by study ID]
Dwinger 2013
Trial name or title Acronym: Intervention Trial to Decrease Cardiovascular Risk in Persons With Serious Mental Illness
(IDEAL)
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: unblinded
Primary purpose: interventional
Participants Condition: those with one ormore diagnoses of the following: diabetes, coronary artery disease, asthma, hy-
pertension, heart failure, chronic obstructive pulmonary disease (COPD), chronic depressionor schizophre-
nia
Enrolment: 1670 participants
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Dwinger 2013 (Continued)
Inclusion criteria
• ≥ 18 years old and insurants of the KKH statutory health insurance
• ≥ 1 diagnoses of the following
◦ Diabetes
◦ Coronary artery disease
◦ Asthma
◦ Hypertension
◦ Heart failure
◦ Chronic obstructive pulmonary disease (COPD)
◦ Chronic depression
◦ Schizophrenia
• For participants with type 2 diabetes, hypertension or coronary artery disease, a risk score for
hospital re-admission will be calculated. If the calculated risk for hospital re-admission within the next
year is greater than 50%, the person will be included in the trial
Exclusion criteria
• Insufficient German language skills
• Hard of hearing
• Not able to read or use a phone
Interventions Intervention(s): telephone-based health coaching
Comparator(s): no coaching (treatment as usual)
Outcomes Primary outcome(s)
• Time from enrolment until hospital re-admission (time frame: 24 months)
Secondary outcome(s)
• Health service use (time frame: 12 months, 24 months and 36 months)
• Health service cost (time frame: 12 months, 24 months and 36 months)
• Frequency of inability to work (time frame: 12 months, 24 months and 36 months)
• Duration of inability to work (time frame: 12 months, 24 months and 36 months)
• Mortality (time frame: 12 months, 24 months and 36 months)
• Quality of life (time frame: 12 months, 24 months and 36 months)
• Depression and anxiety (time frame: 12 months, 24 months and 36 months)
• Alcohol consumption (time frame: 12 months, 24 months and 36 months)
• Medication adherence (time frame:12 months, 24 months and 36 months)
• Physical activity (time frame:12 months, 24 months and 36 months)
• HbA1c (time frame:12 months, 24 months and 36 months)
• Blood pressure (time frame:12 months, 24 months and 36 months)
Other outcome(s)
• Health status with SF-12 (time frame: 12 months, 24 months and 36 months)
• Quality of life (time frame: 12 months, 24 months and 36 months)
• Medication adherence (time frame: 12 months, 24 months and 36 months)
• Medication use for cardiovascular risk factors (time frame: 12 months, 24 months and 36 months)
Starting date Trial start date: 2011
Trial completion date: unknown
Contact information Responsible party/principal investigator: Prof. Martin Härter; m.haerter@uke.de
Study identifier German Clinical Trials Register (Deutsches Register Klinischer Studien, DRKS): DRKS00000584
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Dwinger 2013 (Continued)
Official title Telephone-BasedHealthCoaching forChronically Ill Patients: StudyProtocol for aRandomisedControlled
Trial
Stated purpose of study Quote: “Aim of this study is to evaluate telephone-based health coaching for chronically ill patients in
Germany”
Notes -
NCT00525304
Trial name or title A Self-Management Program for Adults With Both Schizophrenia and a Co-occurring Medical Condition
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: open-label
Primary purpose: supportive care
Participants Condition: schizophrenia
Enrollment: 100 participants
Inclusion criteria
• Meets DSM-IV criteria for schizophrenia or schizoaffective disorder
• Current documented chart diagnosis of ≥ 1 chronic medical condition
• Received clinic services for a minimum of 3 months before trial entry
• English-speaking
• Willing to use an effective form of birth control throughout the trial if sexually active
Exclusion criteria
• History of a serious neurological disorder or head trauma with loss of consciousness
• Diagnosed with mental retardation or dementia
• Diagnosed with end-stage organ disease
• Currently receiving chemotherapy and/or radiation treatment for cancer
• Received psychiatric hospitalisation within 3 months before trial entry date
• Blind and/or deaf
• Pregnant
• Infected with HIV with a CD4 count < 350
• Diagnosis of AIDS
• Diagnosis of anorexia
• Problematic substance use, as defined by a mental health provider
• Psychiatric instability, as defined by a mental health provider
Interventions Intervention(s): behavioural: self management programme for chronic illness. Self management pro-
gramme for chronic illness will include between 10 and 16 psychoeducational and supportive group ses-
sions
Comparator(s): not reported
Outcomes Primary outcome(s)
• Health-related self efficacy and recovery orientation (time frame: measured before and after
intervention)
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NCT00525304 (Continued)
• Medical illness self management skills (time frame: measured before and after intervention)
• Social and communication skills during interactions with healthcare providers (time frame:
measured before and after intervention)
• Physical and mental health status (time frame: measured before and after intervention)
• Medical service use patterns (time frame: measured before and after intervention)
Secondary outcome(s)
• Medication use (time frame: measured throughout the trial)
• Neurocognition (time frame: measured at baseline)
• Substance abuse (time frame: measured before and after intervention)
• Psychiatric symptoms (time frame: measured before and after intervention)
• Quantity and seriousness of related co-morbidities (time frame: measured before and after
intervention)
• Quantitative and qualitative survey ratings (time frame: measured throughout the trial)
Starting date Trial start date: September 2007
Trial completion date: May 2015
Contact information Responsible party/principal investigator: Richard W. Goldberg, PhD; 410-706-8473; rgoldber@psych.
umaryland.edu
Study identifier NCT number: NCT00525304
Official title Optimizing Chronic Illness Self-Management for Individuals With Schizophrenia
Stated purpose of study Quote: “This study will develop and evaluate the effectiveness of a self-management program for adults
living with both schizophrenia and a co-occurring medical condition”
Notes Acccording to ClinicalTrials.gov the information of this record has not been verified recently. Last accessed:
14.04.2016
NCT01410357
Trial name or title Improving Outcomes for Individuals With Serious Mental Illness and Diabetes (TTIM)
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: open-label
Primary purpose: supportive care
Participants Conditions
• Diabetes mellitus
• Bipolar disorder
• Depression
• Psychotic disorders
• Schizophrenia
Enrolment: 212 participants
Inclusion criteria
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NCT01410357 (Continued)
• Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) diagnosis of
schizophrenia, schizoaffective disorder, bipolar disorder or major depression
• DM based upon previous diagnosis or laboratory values
• ≥ 18 years of age
• Able to communicate in English
• Able to provide written, informed consent for participation
Exclusion criteria
• Actively suicidal/homicidal
• Unable to be rated on trial rating scales
• Demented
• Pregnant
• Unable to provide informed consent
Interventions Intervention(s): targeted training in illness management (TTIM): This intervention blends psychoedu-
cation, problem identification/goal setting, behavioural modelling and reinforcement via use of peer edu-
cators and health care linkage; it has been adapted to the primary care setting and targeted for SMI-DM
participants. Generalisability is enhanced by relatively brief in-person participation requirements, and by
inclusion of professional staff typically found in primary care. TTIM will stress information sharing that
is accessible to participants and, through a collaborative process, will foster motivation for severe mental
illness diabetes self management
Comparator(s): treatment as usual (TAU): Participants in this arm will continue to receive treatment as
usual from their usual medical and mental health care providers. They will not receive any intervention
Outcomes Primary outcome(s)
• Change from baseline in Brief Psychiatric Rating Scale (BPRS) at 13 weeks, 30 weeks and 60 weeks
(time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Montgomery Asberg Depression Rating Scale (MADRS) at 13 weeks, 30
weeks and 60 weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Clinical Global Impression (CGI) at 13 weeks, 30 weeks and 60 weeks
(time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Global Assessment of Functioning (GAF) at 13 weeks, 30 weeks and 60
weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Sheehan Disability Scale (SDS) at 13 weeks, 30 weeks and 60 weeks (time
frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in SF-36 Health Survey at 13 weeks, 30 weeks and 60 weeks (time frame:
baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in glycosylated haemoglobin (HbA1c) at 30 weeks and 60 weeks (time frame:
baseline, 30 weeks, 60 weeks)
• Change from baseline in blood pressure at 30 weeks and 60 weeks (time frame: baseline, 30 weeks,
60 weeks)
• Change from baseline in body mass index (BMI) at 30 weeks and 60 weeks (time frame: baseline,
30 weeks, 60 weeks)
• Change from baseline in heart rate at 30 weeks and 60 weeks (time frame: baseline, 30 weeks, 60
weeks)
Secondary outcome(s)
• Change from baseline in Tablets Routine Questionnaire (TRQ) at 13 weeks, 30 weeks and 60 weeks
(time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Self rated Diabetes Self Care Activities (SDSCA) Questionnaire at 13
weeks, 30 weeks and 60 weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
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NCT01410357 (Continued)
• Change from baseline in Alcohol Use Disorders Identification Test (AUDIT) at 13 weeks, 30 weeks
and 60 weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Smoking Index at 13 weeks, 30 weeks and 60 weeks (time frame: baseline,
13 weeks, 30 weeks, 60 weeks)
• Change from baseline in mental health resource utilisation at 13 weeks, 30 weeks and 60 weeks
(time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in medical care resource utilisation at 13 weeks, 30 weeks and 60 weeks (time
frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Drug Abuse Screening Test (DAST-10) at 13 weeks, 30 weeks and 60
weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
Other Outcome Measure(s)
• Change from baseline in Michigan Diabetes Research and Training Center’s Brief Diabetes
Knowledge Test at 13 weeks, 30 weeks and 60 weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Perceived Diabetes Self Management Scale (PDSMS) at 13 weeks, 30
weeks and 60 weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Perceived Mental Health Self Management Scale (PMHSMS) at 13 weeks,
30 weeks and 60 weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Perceived Therapeutice Efficacy Scale for Diabetes (PTES for DM) at 13
weeks, 30 weeks and 60 weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Insight and Treatment Attitudes Questionnaire (ITAQ) at 13 weeks, 30
weeks and 60 weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Multi-dimensional Scale of Perceived Social Support (MSPSS) at 13 weeks,
30 weeks and 60 weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Internalized Stigma for Mental Illness Scale (ISMI) at 13 weeks, 30 weeks
and 60 weeks (time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
• Change from baseline in Barriers to Self Care Scale (BSCS) at 13 weeks, 30 weeks and 60 weeks
(time frame: baseline, 13 weeks, 30 weeks, 60 weeks)
Starting date Trial start date: July 2011
Trial completion date: July 2015
Contact information Responsible party/principal investigator: Martha Sajatovic, MD; Case Western Reserve University
Study identifier NCT number: NCT01410357
Official title Improving Outcomes for Individuals With Serious Mental Illness and Diabetes
Stated purpose of study Quote: “This project tests a model for improving illness self-management among persons who have both
serious mental illness and diabetes and will be performed within a primary care setting at a safety net
hospital system”
Notes Study completed. No study results nor publications available. Last accessed: 14.04.2016
38Self management interventions for type 2 diabetes in adult people with severe mental illness (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
NCT01725815
Trial name or title Acronym: Health Access and Recovery Peer Program (HARP)
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: single-blind (outcomes assessor)
Primary purpose: treatment
Participants Conditions
• Hypertension
• Arthritis
• Coronary artery disease
• Hepatitis
• Diabetes
• Asthma
• Hyperlipidaemia
• HIV
Enrolment: 400
Inclusion criteria
• On CMHC roster of active patients
• Presence of a serious mental illness (schizophrenia, schizoaffective disorder, bipolar disorder, major
depression, obsessive-compulsive disorder, post-traumatic stress disorder)
• Chronic medical condition as noted in the CMHC chart or via self report (hypertension; arthritis;
heart disease; diabetes; asthma/COPD)
Exclusion criteria
• Cognitive impairment based on a score > 3 on a 6-item, validated screener developed for clinical
research
Interventions Intervention(s): behavioural: HARP intervention The HARP intervention is a 6-week, 6-session, group
format intervention designed to improve self management of chronic medical diseases. Each group lasts
90 minutes and includes 8 to 12 attendees. Between groups, participants work with partners from the
group to troubleshoot problems and accomplish action plans identified during the session. At the end of
the programme, monthly alumni groups meet for 6 months to reinforce lessons from the intervention, to
monitor progress and to maintain peer support
Comparator(s): no intervention control
Outcomes Primary outcome(s)
• Health-related quality of life (time frame: 1 year)
Secondary outcome(s)
• Participant activation (time frame: 1 year) health behaviours (time frame: 1 year)
Starting date Trial start date: June 2011
Trial completion date: April 2016
Contact information Responsible party/principal investigator: Benjamin Druss, MD, MPH; Emory University
Study identifier NCT number: NCT01725815
Official title A Peer-Led, Medical Disease Self-Management Program for Mental Health Consumers
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Stated purpose of study Quote: “establish the first fully peer-led, evidence-based intervention for improving physical self-manage-
ment in this vulnerable population”
Notes -
NCT01828931
Trial name or title Lifestyle Intervention for Diabetes and Weight Management in Psychosis (Healthy LIFE)
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment
Participants Conditions
• Type 2 diabetes mellitus
• Schizophrenia
• Schizoaffective disorder
• Schizophreniform disorder
• Bipolar I disorder
• Major depression with psychotic features
• Substance-induced psychosis
• Psychosis
Enrolment: 120 participants
Inclusion criteria
• Between the ages of 18 and 70 years (inclusive)
• DSM-IV-TR diagnosis of one of the psychotic disorders listed above
• Body mass index (BMI) > 25 kg/m2 at the time of enrolment
• Clearly documented diagnosis of type 2 diabetes mellitus or pre-diabetes
• Ability to provide informed consent
• No medical contraindication to participation in weight reduction/exercise programme, determined
in consultation with the primary care physician
• Female participants of childbearing potential, who are using a medically accepted means of
contraception
Exclusion criteria
• Inability to give informed consent
• Currently enrolled in a formal structured weight management programme
• Currently being prescribed medication specifically for weight loss.
• Participants with unstable or active cardiovascular illnesses (myocardial infarction, CHF, etc), active
or end-stage renal disease, unstable thyroid disease, etc.
• Recurrent episodes of diabetic ketoacidosis, seizure or coma without warning or severe
hypoglycaemia
Interventions Intervention(s): lifestyle intervention - a lifestyle intervention based on the Look AHEAD trial interven-
tion, involving counselling related to dietary and physical activity habits
Comparator(s): usual care - standard care provided via participants’ family physicians, diabetes nurses and
psychiatrists
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Outcomes Primary outcome(s)
• Weight (time frame: 52 weeks)
• HbA1c levels (time frame: 52 weeks)
Starting date Trial start date: December 2012
Trial completion date: December 2015
Contact information Responsible party/principal investigator: Margaret K Hahn, MD; Centre for Addiction and Mental
Health
Study identifier NCT number: NCT01828931
Official title Effectiveness of Intensive Lifestyle Interventions in the Management of Diabetes in Individuals With
Psychosis
Stated purpose of study Quote: “We propose a 3-year randomised controlled trial examining the effectiveness of a lifestyle in-
tervention (LI) aimed at reducing caloric intake and increasing physical activity in overweight or obese
individuals (N=150) suffering from both a psychotic illness and T2DM”
Notes -
NCT02011529
Trial name or title Acronym: TEAMcare for Diabetes in Mental Health Centers
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: open-label
Primary purpose: treatment
Participants Condition: type 2 diabetes
Enrollment: 40 participants
Inclusion criteria
• Adult (18 to 70 years)
• Enrolled to receive mental health treatment at Harborview Mental Health Services or Downtown
Emergency Services Mental Health Center
• Diagnosis of type 2 diabetes mellitus or cardiovascular disease
• Hemoglobin A1c > 8 or BP > 140/90
Exclusion criteria
• Cognitive, hearing or language impairment that would preclude a participant from providing
informed consent
• Current suicidality, homicidality or grave disability that requires psychiatric hospitalisation
• Current substance abuse or dependence, as defined by SCID
Interventions Intervention(s): TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes
and psychiatric illness. It involves structured visits with a trial nurse formonitoring of psychiatric symptoms,
control of medical disease and performance of self care activities. Nurses use motivational coaching to help
41Self management interventions for type 2 diabetes in adult people with severe mental illness (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
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participants solve problems and set goals for improved self care and medication adherence. Medications
for diabetes, hypertension and hyperlipidaemia are monitored and therapy intensified on the basis of treat-
to-target guidelines. All of these processes and outcome measures are tracked in a registry designed for
the trial, and nurses receive weekly supervision by a psychiatrist, an endocrinologist and a psychologist to
review new cases and to track progress. Once a participant achieves targeted levels for relevant measures,
the participant and the nurse develop a maintenance plan
Comparator(s): treatment as usual: Participants randomised to treatment as usual will receive their usual
mental health treatment and primary care treatment
Outcomes Primary outcome(s)
• Hemoglobin A1c (time frame: 6 months)
Secondary outcome(s)
• Blood pressure (time frame: 6 months)
• LDL cholesterol (time frame: 6 months)
Other outcome(s)
• Brief Psychiatric Rating Scale (BPRS) (time frame: 6 months)
Starting date Trial start date: November 2013
Trial completion date: September 2015
Contact information Responsibleparty/principal investigator: LydiaChwastiak, Associate Professor,University ofWashington
Study identifier NCT number: NCT02011529
Official title A Team Approach to Improve the Quality of Diabetes Care for Patients With Schizophrenia
Stated purpose of study Quote: “To demonstrate the feasibility and acceptability of adapting TEAMcare for patients with
schizophrenia. The aim of this innovative mental health center-based team intervention is to improve
diabetes, cardiovascular and psychiatric outcomes among patients with poorly controlled type 2 diabetes”
Notes Study completed. No study results nor publications available. Last accessed: 14.04.2016
NCT02127671
Trial name or title Acronym: Intervention Trial to Decrease Cardiovascular Risk in Persons With Serious Mental Illness
(IDEAL)
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: single-blind (outcomes assessor)
Primary purpose: prevention
Participants Condition: 1 of the following CVD risk factors: hypertension, diabetes mellitus or dyslipidaemia
Enrollment: 250 participants
Inclusion criteria
• Age 18 and older
• Body mass index ≥ 25 kg/m2 OR 1 of the following CVD risk factors
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◦ Hypertension (SBP ≥ 140 mmHg or DBP ≥ 90 mmHg or on antihypertensive medications
◦ Diabetes mellitus (fasting blood sugar > 125 mg/dL or haemoglobin A1c > 6.5 or on a
hypoglycaemic medication)
◦ Dyslipidemia (LDL > 130 mg/dL)
• HDL < 40 or total cholesterol ≥ 200 or on a lipid-lowering agent
• Current tobacco smoker
• Able and willing to give informed consent
• Completion of baseline data collection
• Willing to accept randomisation
• Willing to participate in the intervention
Exclusion criteria
• Cardiovascular event (unstable angina, myocardial infarction) within the past 6 months
• Serious medical condition that limits life expectancy or requires active management (e.g. certain
cancers)
• Condition that interferes with outcome measurement (e.g. dialysis)
• Pregnant or planning a pregnancy during trial period. Nursing mothers would need approval from
physician
• Alcohol or substance use disorder if not sober/abstinent for 30 days
• Planning to leave rehabilitation centre or clinic within 6 months or to move out of geographic area
within 18 months
• Investigator judgement (e.g. for concerns about participant or staff safety)
Interventions Intervention(s): individual cardiovascular risk reduction counselling, co-ordination with primary care
providers to ensure appropriate management of risk factors, collaboration with mental health staff and
social supports. All participants will be offered group exercise classes, and programmes will be provided
with instruction to provide more healthy meals
Comparator(s): control - All participants will be offered group exercise classes, and programmes will be
provided with instruction to provide more healthy meals
Outcomes Primary outcome(s)
• Global Framingham Risk Score (time frame: 18 months)
Secondary outcome(s)
• Weight (time frame: 6 and 18 months)
• BMI (time frame: 6 and 18 months)
• Six-minute walk test (time frame: 6 and 18 months)
• Healthy diet (time frame: 6 and 18 months)
• Fasting glucose level (time frame: 6 and 18 months)
• Diabetes mellitus treated to goal (HbA1c) (time frame: 6 and 18 months)
• Smoking cessation (time frame: 6 and 18 months)
• Blood pressure (time frame: 6 and 18 months)
• Hypertension treated to goal (time frame: 6 and 18 months)
• Total cholesterol (time frame: 6 and 18 months)
• LDL cholesterol (time frame: 6 and 18 months)
• HDL cholesterol (time frame: 6 and 18 months)
• Triglycerides (time frame: 6 and 18 months)
• Dyslipidaemia treated to goal (time frame: 6 and 18 months)
Other outcome(s)
• Health status with SF-12 (time frame: 6 and 18 months)
• Quality of life (time frame: 6 and 18 months)
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• Medication adherence (time frame: 6 and 18 months)
• Medication use for cardiovascular risk factors (time frame: 6 and 18 months)
Starting date Trial start date: December 2013
Trial completion date: January 2018
Contact information Responsible party/principal investigator: Gail L. Daumit, MD, MHS; Johns Hopkins University
Study identifier NCT number: NCT02127671
Official title Comprehensive CVD Risk Reduction Trial in Persons With Serious Mental Illness
Stated purpose of study Quote: “This study will determine whether a program where a health coach works with participants on
heart healthy behaviours and treatment of risk factors is coordinated with primary care can reduce overall
heart disease risk in people with serious mental illness”
Notes -
NCT02188732
Trial name or title Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes
Methods Type of trial: interventional
Allocation: randomised
Intervention model: parallel assignment
Masking: single-blind (outcomes assessor)
Primary purpose: supportive care
Participants Conditions
• Schizophrenia
• Schizoaffective disorder
• Bipolar disorder
• Depression
Enrollment: 300
Inclusion criteria
• Age 18 or older and enrolled in treatment for ≥ 3 months
• Severe mental illness as defined by (1) primary DSM-IV (Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition) Axis I diagnosis of schizophrenia, schizoaffective disorder, bipolar
disorder or major depressive disorder; (2) moderate impairment across multiple areas of psychosocial
functioning, including social relationships, self care, community/work activity, treatment self
management and community living skills; (3) GAF (Global Assessment of Functioning) score < 61. A
broad range of severe mental illnesses are included primarily because this will make findings more
generalisable to routine mental health settings, but also because we included this group in our pilot studies
• Diagnosis of 1 of the following medical illnesses or health conditions: diabetes, heart disease, chronic
obstructive pulmonary disease, chronic pain, hyperlipidaemia, hypertension, obesity, tobacco dependence
• Voluntary informed consent for participation in the trial provided by the participant or by the
participant’s legally designated guardian
• An expressed willingness to participate in self management training or a telehealth programme
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• Ability to read the telehealth display in English
Exclusion criteria
• Current residence in a nursing home or group home
• Terminal physical illness expected to result in death of the trial participant within 12 to 24 months
• Primary diagnosis of dementia, co-morbid diagnosis of dementia or significant cognitive
impairment as indicated by a Mini Mental State Examination (MMSE) 74 score < 24
Interventions Intervention(s)
• Experimental: CBHH + AT (Community-Based Health Home + Automated Telehealth): a wireless
telehealth device programmed with psychiatric content corresponding to the primary psychiatric
diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5
to 10 minutes. Branching logic tailors questions or feedback to the user’s responses (e.g. if a participant
endorses medication non-adherence, a question appears asking why medications were not taken). The
device automatically provides specific instructions to participants demonstrating signs of high risk
• Active comparator: CBHH + SMT (Community-Based Health Home + I-IMR Self Management
Training): integrates psychiatric illness self management with strategies for medical illness self
management. The psychiatric component includes psychoeducation about illness and treatment,
cognitive-behavioural approaches to increase medication adherence, training and relapse prevention,
teaching of coping skills for management of persistent symptoms and social skills training. The medical
illness component consists of an individually tailored curriculum focused on managing physical illnesses
by using parallel skills and strategies taught for psychiatric illness self management, as well as a nurse
healthcare manager to facilitate co-ordination of necessary preventive and ongoing health care. The I-
IMR curriculum consists of 10 modules delivered by an I-IMR specialist during eight months of weekly
sessions customised to the specific needs and disorders of each individual
Comparator(s): Community-Based Health Home (CBHH): Each team has a staff-to-participant ratio of
approximately 1:12, and each team serves approximately 120 participants with severe mental illness by
using person-centred planning and recovery-oriented, flexible service models. Each team provides mobile
outreach and includes a team leader; a peer counsellor; a psychiatric nurse co-ordinator; a clinical care co-
ordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employ-
ment and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW)
Outcomes Primary outcome(s)
• Change in health self management (time frame: change from baseline at 4, 8, 12 and 24 months)
◦ Self Rated Abilities for Health Practices Scale
• Change in risk of early mortality (time frame: change from baseline at 4, 8, 12 and 24 months)
◦ Avoidable Mortality Risk Index
• Change in acute service use (time frame: change from baseline at 4, 8, 12 and 24 months)
◦ Emergency room visits and hospitalisations
Secondary outcome(s)
• Change in mental health self management (time frame: change from baseline at 4, 8, 12 and 24
months)
◦ Illness Management and Recovery Scale
• Change in psychiatric symptom severity (time frame: change from baseline at 4, 8, 12 and 24
months)
◦ Brief Psychiatric Rating Scale
• Change in acute care costs (time frame: change from baseline at 12 and 24 months)
◦ Emergency room and hospitalisation costs
Other outcome(s)
• Change in subjective health status (time frame: change from baseline at 4, 8, 12 and 24 months)
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◦ SF-12
• Change in cardiovascular risk factors (time frame: change from baseline at 4, 8, 12 and 24 months)
◦ BMI, tobacco use, blood pressure, glucose, lipids
Starting date Trial start date: September 2014
Trial completion date: August 2019
Contact information Responsible party/principal investigator: Stephen J. Bartels, MD, MS; sbartels@dartmouth,edu; or
Maghan Santos, MSW; maghan.m.santos@dartmouth.edu
Study identifier NCT number: NCT02188732
Official title Self-Management Training and Automated Telehealth to Improve SMI Health Outcomes
Stated purpose of study Quote: “To evaluate outcomes for n=100 in a Community Based Health Home alone (CBHH), compared
to n=100 also receiving Self-Management Training (CBHH+SMT), and n=100 also receiving Automated
Telehealth (CBHH+AT)”
Notes -
NCT02318797
Trial name or title Optimizing Behavioral Health Homes for Adults With Serious Mental Illness (PCORI OH)
Methods Type of trial: interventional
Allocation:randomised
Intervention model: parallel assignment
Masking: single-blind (investigator)
Primary purpose: Health Services Research
Participants Conditions
• Chronic disease
• Mental health
• Behavioural health
• Cardiovascular disease
• Diabetes mellitus type 2
• Substance-related disorder
• Vascular disease
Enrollment: 1229 participants
Inclusion criteria
• Adults age 21 and older
• Serious mental illness (schizophrenia, bipolar disorder, major depression)
• Receive services at 1 of the 11 participating community mental health centres
• At least 1 claim for outpatient case management or peer specialist services
Exclusion criteria
• Not willing to provide informed consent
• Assessed by clinicians as too ill to be treated on an outpatient basis
• Unable to speak, read or understand English at the minimum required level
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Interventions Intervention(s): patient self directed care, patient self management toolkits, web portal with information
on health conditions, personal health care use data, health tracking tools, wellness programmes
Comparator(s): provider-supported integrated care registered nurse on staff at community mental health
centres with access to patient-level physical health information. to work with participants on co-ordinating
their care, to enhance communication between providers and payer and to provide patient wellness support
and education
Outcomes Primary outcome(s)
• Change in patient activation in care (PAM, a 13-item scale) (time frame: baseline and every 6
months over 2-year active intervention period)
◦ Assessed using the PAM, a 13-item scale that renders a total activation score. This measure
gauges the knowledge, skills and confidence of patients essential to managing their own health and health
care. It divides into progressively higher levels of activation: starting to take a role, building knowledge
and confidences, taking action and maintaining behaviours
• Change in health status (SF-12v2™) (time frame: baseline and every 6 months over 2-year active
intervention period)
◦ Health status is measured using the SF-12v2™, a widely used and practical health survey tool
consisting of 12 questions and two subscales for measuring physical and mental health status and
symptom effects and functioning
• Change in engagement in primary/specialty care (frequency of primary/specialty care visits) (time
frame: updated annually using claims data over 2-year active intervention period)
◦ Frequency of primary/specialty care visits over 12-month time periods
Secondary outcome(s)
• Change in hope (Hope Scale) (time frame: baseline and every 6 months over 2-year active
intervention period)
◦ Participant hopefulness will be assessed using the Hope Scale, an instrument designed to
measure hope that has been previously used in health services research. Twelve items are rated on a 4-
point response scale ranging from “definitely false” to “definitely true” and summed to produce a total
score. Research has found Hope Scale scores to be positively associated with goal-related activities and
coping strategies
• Change in quality of life (QLESQ) (time frame: baseline and every 6 months over 2-year active
intervention period)
◦ Participant quality of life is measured using the QLESQ (Quality of Life Enjoyment and
Satisfaction Questionnaire), in which participants respond on a scale of 1 (very poor) to 5 (very good) to
indicate their level of satisfaction with a variety of social and physical domains
• Change in medication adherence (claims data) (time frame: updated annually using claims data over
2-year active intervention period)
◦ Physical health claims data will be obtained to determine the fill rate for psychiatric and
medical medications for participants over 12-month time periods
• Change in functional status (Sheehan Disability Scale) (time frame: baseline and every 6 months
over 2-year active intervention period)
◦ Functional status is measured using the Sheehan Disability Scale, which assesses functional
impairment in 3 domains, including work/school, social and family life. Respondents rate the extent to
which work/school, social life and home life or family responsibilities are impaired by symptoms
• Change in emergent care use (claims data) (time frame: updated annually using claims data over 2-
year active intervention period)
◦ Behavioural and physical health claims data will be obtained to determine frequency of
emergent service use for participants over 12-month time periods
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• Change in lab monitoring (claims data) (time frame: updated annually using claims data over 2-year
active intervention period)
◦ Claims data will be collected regarding the type(s) of lab test performed and service date
• Change in participant satisfaction with care (qualitative interviews) (time frame: qualitative
interviews at baseline, 12 months and 24 months of active intervention
◦ Participant satisfaction with care will be measured using a structured in-depth qualitative
interview guide. Interviews are conducted with a subset of participants from each intervention arm at
baseline, 12 months and 24 months to assess care experiences
Starting date Trial start date: October 2013
Trial completion date: January 2017
Contact information Responsible party/principal investigator: Charles F. Reynolds, MD; University of Pittsburgh; UPMC
Center for High-Value Health Care
Study identifier NCT number: NCT02318797
Official title Optimizing Behavioral Health Homes by Focusing on Outcomes That Matter Most for Adults With
Serious Mental Illness
Stated purpose of study Quote: “test two promising ways for promoting the health, wellness, and recovery of adults with SMI”
Notes -
“-” denotes not reported
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D A T A A N D A N A L Y S E S
This review has no analyses.
A D D I T I O N A L T A B L E S
Table 1. Overview of trial populations
Inter-
vention and
comparator
Sample size
a
Screened/
eligible
[N]
Ran-
domised
[N]
Analysed
[N]
Finishing
trial
[N]
Ran-
domised
finishing
trial
[%]
Follow-upb
McKibbin
2010
I: Dia-
betes Aware-
ness and Re-
habili-
tation Train-
ing (DART)
- 77 32 26 26 81.3 24 weeks (6
months post
interven-
tion)
C: usual care
plus
information
(UCI)
32 26 26 81.3
Total: 64 52 52 81.3
aAccording to power calculation in trial publication or report
bDuration of intervention and/or follow-up under randomised conditions until end of trial
“-” denotes not reported
C: comparator; I: intervention
A P P E N D I C E S
Appendix 1. Search strategies
Cochrane Library
1. [mh “Diabetes Mellitus, Type 2”]
2. (“MODY” or “NIDDM” or T2D*):ti,ab
3. ((“non insulin*” next depend*) or (noninsulin* next depend*) or noninsulindepend* or “non” next “insulindepend*”):ti,ab
4. ((typ* next (2 or II)) near/4 diabet*):ti,ab
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5. (((“late” or adult* or matur* or “slow” or stabl*) near/4 “onset”) and diabet*):ti,ab
6. {or #1-#5}
7. [mh “Diabetes Insipidus”]
8. (diabet* next “insipidus”):ti,ab
9. #7 or #8
10. #6 not #9
11. [mh ˆ“Mental Disorders”]
12. [mh “Affective Disorders, Psychotic”]
13. [mh “Personality disorders”]
14. [mh “Schizophrenia and Disorders with Psychotic Features”]
15. (“mental” near/4 (disorder* or “illness”)):ti,ab
16. (schizo* or psychos?s or “psychotic”):ti,ab
17. ((“bipolar” or “affective” or “personality”) next disorder*):ti,ab
18. [mh ˆ“Depressive Disorder, Major”]
19. ((“major” or “unipolar” or “clinical” or “recurrent”) next depress*):ti,ab
20. {or #11-#19}
21. #10 and #20
MEDLINE (Ovid SP)
1. exp Diabetes Mellitus, Type 2/
2. (MODY or NIDDM or T2D*).tw.
3. (non insulin* depend* or noninsulin* depend* or noninsulin?depend* or non insulin?depend*).tw
4. ((typ? 2 or typ? II or typ?2 or typ?II) adj3 diabet*).tw.
5. (((late or adult* or matur* or slow or stabl*) adj3 onset) and diabet*).tw
6. or/1-5
7. exp Diabetes Insipidus/
8. diabet* insipidus.tw.
9. 7 or 8
10. 6 not 9
11. Mental Disorders/
12. exp Affective Disorders, Psychotic
13. exp Personality disorders/
14. exp “Schizophrenia and Disorders with Psychotic Features”/
15. (mental adj3 (disorder* or illness)).tw.
16. (schizo* or psychos?s or psychotic).tw.
17. ((bipolar or affective or personality) adj disorder*).tw
18. Depressive Disorder, Major/
19. ((major or unipolar or clinical or recurrent) adj depress*).tw
20. or/11-19
21. 10 and 20
22. Patient Education as Topic/
23. Patient Compliance/
24. exp Self Care/
25. exp Health Promotion/
26. exp Behavior Therapy/
27. exp Health Behavior/
28. Program Evaluation/
29. Life style/
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30. Weight Loss/
31. self.tw.
32. (monitor* or manage*).tw.
33. (educat* or knowledge).tw.
34. (behav* or psychoth* or psychosocial).tw.
35. (aware* or adjust*).tw.
36. (adher* or compliance).tw.
37. (intervention? or program? or programme?).tw.
38. (lifestyle or life style).tw.
39. (weight adj3 (management or los* or reduct*)).tw.
40. or/22-39
41. 21 and 40
[42-52: Cochrane Handbook 2008 RCT filter - sensitivity maximizing version]
42. randomised controlled trial.pt.
43. controlled clinical trial.pt.
44. randomi?ed.ab.
45. placebo.ab.
46. drug therapy.fs.
47. randomly.ab.
48. trial.ab.
49. groups.ab.
50. or/42-49
51. exp animals/ not humans/
52. 50 not 51
53. 41 and 52
EMBASE (Ovid SP)
1. non insulin dependent diabetes mellitus/
2. (MODY or NIDDM or T2D*).tw.
3. (non insulin* depend* or noninsulin* depend* or noninsulin?depend* or non insulin?depend*).tw
4. ((typ? 2 or typ? II or typ?2 or typ?II) adj3 diabet*).tw.
5. (((late or adult* or matur* or slow or stabl*) adj3 onset) and diabet*).tw
6. or/1-5
7. exp diabetes insipidus/
8. diabet* insipidus.tw.
9. 7 or 8
10. 6 not 9
11. mental disease/
12. major affective disorder/
13. exp personality disorder/
14. exp psychosis/
15. (mental adj3 (disorder* or illness)).tw.
16. (schizo* or psychos?s or psychotic).tw.
17. ((bipolar or affective or personality) adj disorder*).tw
18. major depression/
19. ((major or unipolar or clinical or recurrent) adj depress*).tw
20. or/11-19
21. 10 and 20
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22. exp health education/
23. exp patient attitude/
24. exp self care/
25. behavior therapy/
26. exp health behavior/
27. exp program evaluation/
28. lifestyle/
29. weight reduction/
30. weight control/
31. self.tw.
32. (monitor* or manage*).tw.
33. (educat* or knowledge).tw.
34. (behav* or psychoth* or psychosocial).tw.
35. (aware* or adjust*).tw.
36. (adher* or compliance).tw.
37. (intervention? or program? or programme?).tw.
38. (lifestyle or life style).tw.
39. (weight adj3 (management or los* or reduct*)).tw.
40. or/22-39
41. 21 and 40
[42: Wong 2006a“sound treatment studies” filter - BS version]
42. random*.tw. or clinical trial*.mp. or exp health care quality/
43. 41 and 42
44. limit 43 to embase
PsycINFO (Ovid SP)
1. Diabetes Mellitus/
2. (MODY or NIDDM or T2D*).tw.
3. (non insulin* depend* or noninsulin* depend* or noninsulin?depend* or non insulin?depend*).tw
4. ((typ? 2 or typ? II or typ?2 or typ?II) adj3 diabet*).tw.
5. (((late or adult* or matur* or slow or stabl*) adj3 onset) and diabet*).tw
6. or/1-5
7. Diabetes Insipidus/
8. diabet* insipidus.tw.
9. 7 or 8
10. 6 not 9
11. Mental Disorders/
12. exp Affective Disorders/
13. exp Personality Disorders/
14. exp Psychosis/
15. (mental adj3 (disorder* or illness)).tw.
16. (schizo* or psychos?s or psychotic).tw.
17. ((bipolar or affective or personality) adj disorder*).tw
18. exp Major Depression/
19. ((major or unipolar or clinical or recurrent) adj depress*).tw
20. or/11-19
21. 10 and 20
22. Health Education/ or Health Literacy/ or Client Education/
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23. Disease Management/ or Coping Behavior/ or Self Care Skills/
24. Health Behavior/ or Treatment Compliance/
25. Health Promotion/ or Health Attitudes/
26. “Physical Illness (Attitudes Toward)”/ or Illness Behavior/
27. exp Program Evaluation/
28. exp Behavior Therapy/
29. exp Lifestyle/
30. Weight Loss/ or Weight Control/
31. self.tw.
32. (monitor* or manage*).tw.
33. (educat* or knowledge).tw.
34. (behav* or psychoth* or psychosocial).tw.
35. (aware* or adjust*).tw.
36. (adher* or compliance).tw.
37. (intervention? or program? or programme?).tw.
38. (lifestyle or life style).tw.
39. (weight adj3 (management or los* or reduct*)).tw.
40. or/22-39
41. 21 and 40
[42: Eady 2008“PsycInfo Search Strategies” filter - BS version]
42. control*.tw. OR random*.tw. OR exp Treatment/
43. 41 and 42
CINAHL (via EBSCO)
S1 MH “Diabetes Mellitus, Type 2+”
S2 TX (MODY OR NIDDM OR T2D*)
S3 TX (“non insulin* depend*” OR “noninsulin* depend*” OR noninsulin#depend* OR “non insulin#depend*”)
S4 TX ((“typ* 2” OR “typ* II” OR typ#2 OR typ#II) N3 diabet*)
S5 TX (((late OR adult* OR matur* OR slow OR stabl*) N3 onset) AND diabet*)
S6 S1 OR S2 OR S3 OR S4 OR S5
S7MH“MentalDisorders”ORMH“MentalDisorders, Chronic”ORMH“PsychoticDisorders+”ORMH“PersonalityDisorders+”
OR (MH “Depression+”)
S8 TX (mental N3 (disORder* OR disease* OR illness))
S9 TX (schizo* OR psychos#s OR psychotic)
S10 TX ((bipolar OR affective OR personality) N1 disorder)
S11 TX ((major OR unipolar OR clinical OR recurrent) N1 depress*)
S12 S7 OR S8 OR S9 OR S10 OR S11
S13 S6 AND S12
S14MH “Health Education+” ORMH “Health Behavior+” ORMH “Coping” ORMH “Self Care+” ORMH “Health Promotion”
S15 MH “Behavior Therapy+” OR MH “Program Evaluation”
S16 MH “Life Style+” OR MH “Weight Loss” OR MH “Weight Control”
S17 TX (self OR monitor* OR manage* OR educat* OR knowledge OR behav* OR psychoth* OR psychosocial OR aware* OR
adjust* OR adher* OR compliance)
S18 TX (intervention# OR program# OR programme# OR lifestyle OR “life style”)
S19 TX (weight N3 (management OR los* OR reduct*))
S20 S14 OR S15 OR S16 OR S17 OR S18 OR S19
S21 S13 AND S20
[S22: Wong 2006b“therapy studies” filter - BS version]
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S22 MH “prognosis+” OR MH “study design+” OR random*
S23 S21 AND S22
ICTRP Search Portal (Standard search)
diabet* AND mental illness* OR
diabet* AND mental disorder* OR
diabet* AND mental disease* OR
diabet* AND schizo* OR
diabet* AND psychosis OR
diabet* AND psychoses OR
diabet* AND psychotic OR
diabet* AND bipolar OR
diabet* AND affective disorder* OR
diabet* AND personality disorder* OR
diabet* AND major depress* OR
diabet* AND unipolar depress* OR
diabet* AND clinical depress* OR
diabet* AND recurrent depress* OR
diabet* AND severe depress*
ClinicalTrials.gov (Advanced search)
Search Terms: (diabetes OR diabetic) AND (mental OR schizophrenia OR psychosis OR psychoses OR psychotic OR bipolar OR
affective OR personality OR major depression OR major depressive OR clinical depression OR unipolar depression OR recurrent
depression)
Study Type: Interventional Studies
Age Group: Adult, Senior
Appendix 2. Description of interventions
Intervention Comparator
McKibbin 2010 The Diabetes Awareness and Rehabilitation Training
(DART) intervention was a group, face-to-face, 24-
week self management programme. DART comprised
3 modules: (1) basic diabetes education (sessions 1 to 4,
repeated at sessions 13 to 16); (2) nutrition (sessions 5 to
8, repeated at sessions 17 to 20); and (3) lifestyle exercise
(sessions 9 to 12, repeated at sessions 21 to 24). Each
module contained four 90-minute manualised sessions.
Basic education included an explanation of motivation
and a review of blood sugar in symptoms of low and
high blood sugar, diabetes complications, how to use a
glucose meter, doctor visits and how to talk with your
Usual care plus information (UCI) consisted of usual
care delivered by participants’ providers and 3 brochures
provided by the AmericanDiabetes Association relevant
to diabetes management (i.e. basic diabetes education,
nutrition, exercise)
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doctor and medication. Nutrition education included
a review of food groups, portion sizes, healthy meals
and food labels, and replacing sugar with fat and fibre.
Lifestyle and exercise education reviewed different types
of exercise, how exercise impacts blood sugar, tracking
exercise using a pedometer and foot care during exercise
Personnel adapted educational materials for people of
middle age and older with schizophrenia by introducing
1 or 2 topics per session, providing an overview and
summary of the materials, implementing a teach and
query training method, using mnemonic aids and print
materials with larger font and limiting text. Participants
were given simple guidelines about how theymight lead
a healthier lifestyle, such as switching from regular soda
or fruit punch to diet soda or water
One diabetes-trained mental health professional deliv-
ered the intervention. These facilitators did not make
contact with participants’ healthcare providers, and they
encouraged participants to speak with their physician
about their diabetes and provided guidance on how to
record laboratory results and examination findings
Appendix 3. Baseline characteristics (I)
Intervention
and comparator
Duration of in-
tervention
(duration of
follow-up)
Description of
participants
Trial period
(year to year)
Country Setting
McKibbin 2010 I: DART 24 weeks (6
months post in-
tervention)
Participants with
type 2 diabetes
and schizophre-
nia/schizoaffec-
tive disorder
- USA Community
C: UCI C: UCI
“-” denotes not reported
C: comparator; DART: Diabetes Awareness and Rehabilitation Training; UCI: usual care plus information; I: intervention; SD:
standard deviation
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Appendix 4. Baseline characteristics (II)
Intervention
and compara-
tor
Sex
[female %]
Age
[mean years
(SD)]
Ethnicity
[%]
Duration of
diabetes
[mean years
(SD)]
Type of
severe mental
illness
[%]
Age of onset
of
severe mental
illness
[mean years
(SD)]
McKibbin
2010
I: DART 38 52 (10.1) White: 45
African Amer-
ican: 31
Hispanic: 17
Asian: 7
Native Ameri-
can: 0
8.9 (5.8) Schizophre-
nia: 79
Schizoaffec-
tive: 21
25.7 (12.3)
C: UCI 38 54 (8.4) White: 72
African Amer-
ican: 10
Hispanic: 7
Asian: 3
Native Ameri-
can: 7
8.6 (6.5) Schizophre-
nia: 90
Schizoaffec-
tive: 10
29.3 (11.8)
“-” denotes not reported
C: comparator; DART: Diabetes Awareness and Rehabilitation Training; I: intervention; SD: standard deviation; UCI: usual care
plus information
Appendix 5. Baseline characteristics (III)
Inter-
vention and
comparator
HbA1c
[mean %
(SD)]
BMI
[mean kg/
m² (SD)]
Diastolic
blood pres-
sure
[mean
mmHg
(SD)]
Systolic
blood pres-
sure
[mean
mmHg
(SD)]
Glu-
cose control
agents
[%]
Antipsy-
chotic med-
ication
[%]
Comor-
bidities
[%]
McKibbin
2010
I: DART 7.4 (2.9) 33.6 (6.8) 83 (10) 134 (17) Diet only:
15
Oral agent
only: 69
Insulin only:
12
Oral agent
and insulin:
Apripipra-
zole or
ziprasidone:
25
Risperi-
done or que-
tiapine: 46
Cloza-
-
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4 pine or olan-
zapine: 29
C: UCI 6.7 (2.1) 32.9 (6.2) 85 (13) 132 (15) Diet only:
10
Oral agent
only: 72
Insulin only:
3
Oral agent
and insulin:
14
Apripipra-
zole or
ziprasidone:
21
Risperi-
done or que-
tiapine: 48
Cloza-
pine or olan-
zapine: 313
-
“-” denotes not reported
BMI: body mass index; C: comparator; DART: Diabetes Awareness and Rehabilitation Training; HbA1c: glycosylated haemoglobin
A1c; I: intervention; SD: standard deviation; UCI: usual care plus information
Appendix 6. Matrix of trial endpoints (publications and trial documents)
Endpoints quoted in
trial document(s)
(ClinicalTrials.gov,
FDA/EMA document,
manufacturer’s website,
published design paper)
a
Trial results posted
in trial register
[Yes/No]
Publications specified
in trial register
[No/Citation]
Endpoints quoted in
publicationb
McKibbin 2010 N/T No No Diabetes knowledge, self
efficacy (Leutwyler 2010
(see McKibbin 2006)
Weight, body mass index,
waist
circumference, blood pres-
sure, fasting blood glucose,
HbA1c, cholesterol, high-
density lipopro-
tein, low-density lipopro-
tein, triglycerides, diabetes
knowledge, self efficacy,
energy expenditure, activ-
ity levels, total kilocalo-
ries consumed, total min-
utes of activity (McKibbin
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2006)
BMI, weight, waist cir-
cumference, HbA1c, dia-
betes knowledge, energy
expenditure (McKibbin
2010)
aTrial document(s) refers to all available information from published design papers and sources other than regular publications (e.g.
FDA/EMA documents, manufacturer’s websites, trial registers)
bPublication refers to trial information published in scientific journals (primary reference, duplicate publications, companion docu-
ments or multiple reports of a primary trial)
EMA: European Medicines Agency; FDA: Food and Drug Administration (US); N/T: no trial document available
Appendix 7. Examination of outcome reporting bias according to ORBIT classification
Outcome High risk of bias
(category A)a
High risk of bias
(category D)b
High risk of bias
(category E)c
High risk of bias
(category G)d
McKibbin 2010 Self care behaviours N/A N/A Total activity, total
calo-
ries consumed and
total minutes of ac-
tivity were measured
immediately follow-
ing the intervention,
but not at 6-month
follow-up, and were
not analysed as an
outcomewhenmod-
erating effects
of symptoms on ef-
fectiveness of the in-
tervention were ex-
plored. Total energy
expenditure
was measured both
immediately follow-
ing the intervention
and at 6-month fol-
low-up but was not
analysed as an out-
come when moder-
ating effects
of symptoms on ef-
N/A
58Self management interventions for type 2 diabetes in adult people with severe mental illness (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
fectiveness of the in-
tervention were ex-
plored
Diabetes-related
complications
N/I N/I N/I N/I
Adverse events N/I N/I N/I N/I
All-cause mortality N/I N/I N/I N/I
Self efficacy N/A N/A Self ef-
ficacy was measured
and analysed imme-
diately following the
intervention andwas
analysed as an out-
come when moder-
ating effects
of symptoms on ef-
fectiveness of the in-
tervention were ex-
plored. Self efficacy
at 6 months post in-
tervention was not
reported
Progression of severe
mental illness
N/A N/A Symptoms
were measured at
baseline and follow-
ing the intervention
by the PANSS and
the Hamilton De-
pression Scale, as in-
dicated in Leutwyler
2010 (see McKibbin
2006), but these re-
sults are not reported
in McKibbin 2006
nor McKibbin 2010
N/A
HbA1c N/A N/A HbA1c
wasmeasured imme-
diately following the
intervention and at
6-month follow-up
but was not looked
at as an outcome
N/A
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whenmoderating ef-
fects of symptomson
effective-
ness of the interven-
tion were explored
Body mass index N/A N/A BMI was measured
and analysed imme-
diately following the
intervention and at
6-month follow-up
but was not looked
at as an outcome
whenmoderating ef-
fects of symptomson
effective-
ness of the interven-
tion were explored
N/A
Weight N/A N/A Weight was mea-
sured and analysed
immediately follow-
ing the intervention
and at 6-month fol-
low-up but was not
looked at as an out-
come when moder-
ating effects
of symptoms on ef-
fectiveness of the in-
tervention were ex-
plored
N/A
Blood pressure N/A N/A Blood pressure was
measured and anal-
ysed
immediately follow-
ing the intervention,
but results are not
reported at 6-month
follow-up and were
not analysed as an
outcomewhenmod-
erating effects
of symptoms on ef-
fectiveness of the in-
tervention were ex-
plored
N/A
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Change in antipsy-
chotic treatment
type
The arti-
cle reports no signif-
icant changes in an-
tipsychotic
treatment type from
baseline to 6-month
follow-up; however,
no data were pro-
vided
N/A N/A N/A
Change in diabetes
treatment type
The
article reports no sig-
nificant changes in
antipsychotic treat-
ment type between
trial arms over time;
however, no data
were provided
N/A N/A N/A
Socioeconomic
effects
N/I N/I N/I N/I
aClear that outcome was measured and analysed; trial report states that outcome was analysed but reports only that result was not
significant
(Classification ’A’, table 2, Kirkham 2010)
bClear that outcome was measured and analysed; trial report states that outcome was analysed but reports no results
( Classification ’D’, table 2, Kirkham 2010)
cClear that outcome was measured but was not necessarily analysed; judgement says likely to have been analysed but not reported
because of non-significant results
(Classification ’E’, table 2, Kirkham 2010)
dUnclear whether outcome was measured; not mentioned, but clinical judgement says likely to have been measured and analysed but
not reported on the basis of non-significant results
(Classification ’G’, table 2, Kirkham 2010)
N/A: not applicable N/I: not investigated
Appendix 8. Definition of endpoint measurement (I)
Self care be-
haviours
[IO, SO]a
Diabetes-
re-
lated com-
plications
Adverse
events
All-cause
mortality
Health-re-
lated qual-
ity of life
Diabetes
knowledge
[SO]a
Self efficacy
[SO]a
Progres-
sion of se-
vere mental
illness
[SO]a
McKibbin
2010
For measure
of dietary in-
N/I N/I N/I N/I 23-Item dia-
betes knowl-
28-Item Di-
abetes Em-
Depressive
symptom
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take, partic-
ipants were
asked
to rank how
often they
consumed
70 different
foods in the
past month
on the Block
Brief
2000 Revi-
sion of the
Health and
Habits
and History
Question-
naire. Out-
come is total
calories con-
sumed,
lower is pos-
itive (SO)
For measure
of
physical ac-
tivity, partic-
ipants com-
pleted the
Yale Physical
Ac-
tivity Scale
(YPAS). The
YPAS pro-
vides 2 in-
dices:
total energy
expendi-
ture (TEE)
and total ac-
tivity sum-
mary in-
dex (TASI).
Higher
scores
are positive
(SO)
Physical
edge
test. Higher
scores reflect
greater
knowledge
(SO)
power-
ment Scale.
Higher
scores reflect
higher con-
fidence (SO)
sever-
ity was mea-
sured us-
ing the 28-
item Hamil-
ton Depres-
sion
Rating Scale
(HAM-D)
. Unable to
tell whether
higher is
positive
(SO)
Posi-
tive and neg-
ative mood
was mea-
sured using
the Positive
and Nega-
tive Syn-
drome Scale
(PANSS)
. Unable to
tell whether
higher is
positive
(SO)
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activity
was also
measured
by an ac-
celerometer
(AM7164)
(Computer
Science and
Applications
(CSA),
a small,
lightweight
device that
is worn on a
belt around
the waist.
The number
of minutes
of moderate
and vigor-
ous activity
(MVA) was
derived
for each
valid day of
monitoring
(i.e. ≥ 3
days of data,
10 hours
per day) and
averaged
across those
days. Higher
scores posi-
tive (IO)
aMethod of endpoint evaluation.
AO: adjudicated outcome measurement; IO: investigator-assessed outcome measurement; SO: self reported outcome measurement
N/I: not investigated
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Appendix 9. Definition of endpoint measurement (II)
HbA1c
[AO]a
Body mass in-
dex
[SO]a
Weight
[SO]a
Blood pressure
[IO]a
Change in med-
ication or in-
tensity of drug
treatment
Socioeconomic
effects
McKibbin 2010 A 10-mL blood
sample was col-
lected after a 12-
hour fast andwas
assayed by the
UCSD Clinical
Research Center
using established
protocols. Lower
scores are posi-
tive (IO)
Calculated
from height and
weight as kg/m2
mea-
sured at awaken-
ing in light cloth-
ing. Lower scores
are positive (IO)
Weight in kg
mea-
sured at awaken-
ing in light cloth-
ing. Lower scores
are positive (IO)
A single-seated
blood pressure
reading was ob-
tained after a 5-
minute rest with
a validated au-
tomated oscillo-
metric sphygmo-
manometric de-
vice (Omron
model HEM-
705-CP, Omron
Healthcare Inc.
, Vernon Hills,
IL, USA). Biceps
circumference
was measured to
select the appro-
priate size cuff,
and participants
were seated with
the forearm rest-
ing on the table.
Lower scores are
positive (IO)
N/I N/I
aMethod of endpoint evaluation. AO: adjudicated outcome measurement; IO: investigator-assessed outcome measurement; SO: self
reported outcome measurement
HbA1c: glycosylated haemoglobin A1c; N/I: not investigated
Appendix 10. Survey of trial investigators providing information on included trials
Date trial author con-
tacted
Date trial author replied Date trial author was
asked for additional in-
formation
[short summary]
Date trial author pro-
vided data
[short summary]
McKibbin 2010 08/07/15
12/10/15
08/07/15
No reply
• Asked for
clarification on the Table
For Table 1 in 2010 pa-
per, the column on the
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headings in the 2010
paper, as it was unclear
which was the
intervention and which
the control group, along
with numbers
• Asked for the
following information:
Of the 64 participants
who consented into the
trial, how many were
randomised to the
intervention and how
many to the control
group. Of the reasons
stated for drop-out, are
you able to break these
data down by group? (for
both 6 and 12 months
post intervention) Could
you tell us the start and
end dates of the trial?
What blinding was
undertaken? Specifically
in relation to participant,
personnel and outcome
assessors (by outcome if
relevant). Which method
of random sequence
generation did you use?
Was it a 1-to-1 ratio? Was
allocation concealment
achieved? Did you use
any specific diagnostic
criteria for type 2 diabetes
and schizophrenia/
schizoaffective disorder?
How many sites were
recruiting into the trial,
and from where were
people recruited? Did you
have a run-in period? Was
the trial registered on a
database?
right should reflect the
DART programme partic-
ipant data. Twenty-six par-
ticipants were included in
each arm for 6-month fol-
low-up
DART: Diabetes Awareness and Rehabilitation Training
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Appendix 11. Checklist to aid consistency and reproducibility of GRADE assessments
Diabetes-
re-
lated com-
plications
All-cause
mortality
Adverse
events
Health-re-
lated qual-
ity of life
Self care be-
haviours
HbA1c Socioe-
conomic ef-
fects
Trial limita-
tions
(risk of
bias)a
Was random
sequence
genera-
tion used (i.
e. no poten-
tial for selec-
tion bias)?
N/A N/A N/A N/A Unclear Unclear N/A
Was allo-
cation con-
cealment
used (i.e. no
potential for
selection
bias)?
Unclear Unclear
Were partic-
ipants and
personnel
blinded (i.e.
no potential
for perfor-
mance bias)?
Unclear Unclear
Was out-
come assess-
ment
blinded (i.e.
no potential
for detection
bias)?
Unclear Unclear
Was an ob-
jective out-
come used?
No () Yes
Were more
than 80% of
par-
ticipants en-
rolled in tri-
als included
in the anal-
Yes Yes
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ysis (i.e. no
potential re-
porting bias)
?e
Were data
re-
ported con-
sistently for
the outcome
of interest (i.
e. no poten-
tial selective
reporting)?
No () No ()
No other bi-
ases
reported (i.
e. no poten-
tial for other
bias)?
Yes Yes
Did
trials end up
as scheduled
(i.e.
not stopped
early)?
Yes Yes
Inconsis-
tencyb
Point
estimates
did not vary
widely?
Yes Yes
To what ex-
tent did con-
fidence in-
tervals over-
lap (substan-
tial: all con-
fi-
dence inter-
vals overlap
at least 1 in-
cluded stud-
ies point es-
timate;
some: confi-
dence inter-
N/A N/A
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vals but not
all overlap at
least 1 point
esti-
mate; no: at
least 1 out-
lier: where
the confi-
dence inter-
vals of some
studies do
not overlap
with those of
most in-
cluded stud-
ies)?
Was the di-
rection of ef-
fect consis-
tent?
N/A N/A
What was
the magni-
tude of sta-
tistical het-
erogeneity
(asmeasured
by I²) - low
(I² < 40%),
moderate (I²
= 40% to
60%), high
I² > 60%)?
N/A N/A
Was the test
for hetero-
geneity sta-
tistically sig-
nificant (P
value < 0.1)?
N/A N/A
Indirect-
nessa
Were
the popula-
tions in in-
cluded stud-
ies applica-
ble to the de-
cision con-
text?
Highly ap-
plicable
Highly ap-
plicable
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Were the in-
terven-
tions in in-
cluded stud-
ies applica-
ble to the de-
cision con-
text?
Highly ap-
plicable
Highly ap-
plicable
Was the in-
cluded out-
come not a
surrogate
outcome?
No () No ()
Was the out-
come time
frame suffi-
cient?
Sufficient Sufficient
Were the
conclusions
based on di-
rect compar-
isons?
Yes Yes
Impreci-
sionc
Was the con-
fidence in-
terval for the
pooled
estimate not
consistent
with benefit
and harm?
N/A N/A
What is the
magnitude
of the me-
dian sample
size (high:
300 partici-
pants, inter-
me-
diate: 100 to
300 partici-
pants, low: <
100 partici-
pants)?e
Low () Low ()
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(Continued)
What
was themag-
nitude
of the num-
ber of in-
cluded stud-
ies (large:
> 10 studies,
moderate: 5
to 10 stud-
ies, small: <
5 studies)?e
Small () Small ()
Was the out-
come a com-
mon event
(e.g.
occurs more
than 1/100)
?
N/A N/A
Publication
biasd
Was a com-
prehensive
search con-
ducted?
Yes Yes
Was grey lit-
erature
searched?
Yes Yes
Were no re-
strictions
applied to
study selec-
tion on the
basis of lan-
guage?
Yes Yes
Was no in-
dustry influ-
ence noted
in studies in-
cluded in
the review?
Yes Yes
Was no evi-
dence of
funnel plot
asymmetry
N/A N/A
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found?
Was no dis-
crepancy in
findings
noted be-
tween pub-
lished
and unpub-
lished trials?
Unclear Unclear
aQuestions on risk of bias are answered in relation to most of the aggregated evidence in the meta-analysis rather than to individual
trials
bQuestions on inconsistency are based primarily on visual assessment of forest plots and statistical quantification of heterogeneity
based on I²
cWhen judging the width of the confidence interval, it is recommended to use a clinical decision threshold to assess whether the
imprecision is clinically meaningful
dQuestions address comprehensiveness of the search strategy, industry influence, funnel plot asymmetry and discrepancies between
published and unpublished trials
eDepends on the context of the systematic review area
(): key item for possible downgrading of the quality of the evidence (GRADE) as shown in the footnotes of the ’Summary of finding’
table(s); GRADE: Grading of Recommendations Assessment, Development and Evaluation; N/A: not applicable
C O N T R I B U T I O N S O F A U T H O R S
Hayley McBain (HM): protocol draft, search strategy development, acquisition of trial reports, trial selection, data extraction, data
analysis, data interpretation, review of drafts and future review updates.
KathleenMulligan (KM): protocol draft, search strategy development, data extraction, data analysis, data interpretation, review of draft
and future review updates.
Mark Haddad (MH): protocol draft, trial selection, data analysis, data interpretation, review of draft and future review updates.
Chris Flood (CF): protocol draft, trial selection, data analysis, data interpretation, review of draft and future review updates.
Julia Jones (JJ): protocol draft, data analysis, data interpretation, review of draft and future review updates.
Alan Simpson (AS): protocol draft, data extraction, data analysis, data interpretation, review of draft and future review updates
D E C L A R A T I O N S O F I N T E R E S T
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The protocol specified that review authors would search the Allied and Complementary Medicine Database (AMED) for articles;
however, on advice from the Trials Search Co-ordinator in the Cochrane Metabolic and Endocrine Disorders Group, we removed this
database from the search strategy.
N O T E S
Portions of the background and methods sections, the appendices, additional tables and Figures 1 to 3 of this review are based on a
standard template established by the Cochrane Metabolic and Enocrine Disorders Group.
We have based parts of the background and methods sections, the appendices, additional tables and Figures 1 to 3 of this review on a
standard template established by the Cochrane Metabolic and Enocrine Disorders Group.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Diabetes Mellitus, Type 2 [psychology; ∗therapy]; Mental Disorders [∗complications]; Randomized Controlled Trials as Topic; Self
Care [∗methods]
MeSH check words
Adult; Humans
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